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ABSTRACT 
Glioblastoma Multiforme (GBM) is a highly invasive brain tumor that 
affects approximately 18,000 people annually in the USA alone yet remains 
without curative treatment. Median survival with treatment is 14 months, with 
most treatments only prolonging life for several months while causing severe 
adverse side effects. There is a need for new therapeutic modalities. Herein I 
explore two small molecules that show promise in modulating inflammatory 
signaling in an in vitro GBM model. Indirubins E804 (indirubin-3’-(2,3 
dihydroxypropyl)-oximether) and 7BIO (7-Bromoindirubin-3’-oxime) are synthetic 
derivatives of natural indirubin. Natural indirubin is a bisindole alkaloid derived 
from tryptophan precursors and is an agonist for the ligand-activated transcription 
factor aryl hydrocarbon receptor (AHR). Indirubin has been shown to disrupt 
important cancer-driving signaling such as JAK/STAT3, GSK3, and CDKs. To 
determine AHR pathway significance in my results, I added a selective AHR 
antagonist, 6,2’,4’-trimethoxyflavone (TMF), in addition to indirubins. Herein I 
show that E804 modulates a large array of inflammatory genes, including down-
regulation of important autocrine GBM signaling molecules like IL-6 and VEGF, 
which help drive tumor development. 7BIO, but not E804, increased the 
expression of STAT3, suggesting that this compound is not suitable for glioma 
therapy. Additional studies showed that E804 does not fully activate the unfolded 
protein response (UPR). The UPR is an ER stress pathway that can induce 
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indiscriminate apoptosis - an undesirable side effect in an area as sensitive as 
the brain. Finally, using transcriptomics combined with pathway analysis, I 
examined the effects that E804- or E804+TMF-treated glioblastoma cells have on 
differentiated THP-1 macrophages to model the effects that gliomas may have on 
glioma-associated macrophages. Glioma-associated macrophages can comprise 
up to 30% of GBM mass, and, if activated by certain glioma-derived signals, have 
been implicated in tumor promotion. I found that treated-GBM supernatants 
inhibited gene profiles in THP-1 macrophages that are linked to tumor 
progression, such as the Wnt, TLR, and Cell Cycle pathways; enriched gene 
ontology (GO) terms in up-regulated gene lists involving vascularization and 
hormone metabolism; and modulated expression of genes associated with 
macrophage polarization. Taken together, the results of this study demonstrate 
that E804 and E804 + TMF modulate signaling in GBM cells, with the ability to 
influence macrophages. These treatments hold promise as an alternative to 
current modalities using very toxic nitrosourea compounds, and future work 
should continue to investigate crosstalk between macrophages and GBM, both in 
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LITERATURE REVIEW 
Glioblastoma Multiforme (GBM) and current state of the field 
Gliomas account for 30% of all primary brain and central nervous system 
(CNS) cancers (National Brain Tumor Society , Goodenberger and Jenkins 
2012). Of the four WHO-defined malignancy grades, Glioblastoma Multiforme 
(GBM) ranks as the most aggressive and fatal of the gliomas (grade IV) and 
boasts 17,000 new diagnoses in the US per year (Holland 2000, National Cancer 
Institute). Found mainly in the cerebral hemispheres, GBM may arise from 
astrocytes, but other cell types may contribute as well, including neuronal and 
oligodendrocyte precursors (Zong, Verhaak, and Canoll 2012, Zong, Parada, and 
Baker 2015, Alcantara Llaguno and Parada 2016), which may determine the 
origin and nature of glioma stem cells (Jackson, Hassiotou, and Nowak 2014). 
While GBM rarely metastasizes to other organs (Hamilton et al. 2014), it is a 
diffuse tumor and can spread to any region of the spinal cord or brain (American 
Brain Tumor Association 2014, Alifieris and Trafalis 2015). Diagnosis rarely 
occurs prior to the onset of severe neurological symptoms due to brain pressure. 
Even with treatment GBM has a dismal prognosis, at 25% overall survival after 2 
years (van Tellingen et al. 2015). While many experimental drugs exist, none 
have achieved a cure for GBM. 
The pathogenesis of GBM is the subject of intense debate, and may 
depend on the subtype. Based on intrinsic transcriptional profiles, pro-neural, 
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neural, mesenchymal, and classical types are recognized (Verhaak et al. 2010). 
Genotypic classification seems to determine phenotypic constitution seen upon 
histopathological examination (Wang et al. 2017, Joo et al. 2013) and molecular 
lesions can vary widely among these subtypes. Multiple copies of endothelial 
growth factor receptor (EGFR) and alterations in both chromosome 10 and 7 
characterize the classical subtype (Kuehn 2010). Mutations in p53, platelet-
derived growth factor receptor alpha (PDGFRA), and isocitrate dehydrogenase 1 
(IDH1) are more typical of the pro-neural subtype, while high rates of mutation in 
both 0-6-methylguanine-DNA methyltransferase (MGMT) and IDH1 are typical of 
the neuronal subtype (Molenaar et al. 2014). High rates of mutation in 
neurofibromatosis type 1 (NF1) are typical of the mesenchymal subtype. 
Although glioblastoma cannot be cured surgically, the first management 
step is to debulk as much of the tumor as possible. Following surgery, GBM is 
often treated using radiotherapy, chemotherapy, and possibly immunotherapy 
with the goal of slowing tumor growth. No current treatments are completely 
curative (Young et al. 2015). Chemotherapy options include alkylating agents 
such as temozolomide (TMZ), delivered orally, and carmustine, delivered as an 
infused wafer directly to the brain (Ramirez et al. 2013). Oral medications such 
as TMZ have difficulty crossing the blood-brain barrier, and implantation of 
carmustine-infused biodegradable polymers has limited success with high risk of 
brain edema and infection (Omuro and DeAngelis 2013). The work presented 
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herein may lead to an alternative, or at least concomitant, treatment plan that 
could be applied to infusible biodegradable polymers. 
GBM are highly vascularized tumors, thus anti-angiogenic treatments 
have long been pursued (McNamara and Mason 2012). Bevacizumab is a 
monoclonal antibody targeting vascular endothelial growth factor (VEGF) and is 
usually used in tandem with temozolomide. However, new evidence implies that 
anti-VEGF therapies alone are insufficient, and may in fact contribute to later 
tumor invasion (Keunen et al. 2011). Anti-VEGF Bevacizumab in combination 
with glycolytic pathway targeting therapies have been suggested as a potential 
solution. Ultimately it is the persistent, rather than transient, normalization of 
vasculature hypothesized to decrease tumor growth and perhaps aid in 
therapeutic efficacy (Huang et al. 2013). Regardless, Bevacizumab is often used 
only as a salvage treatment, as its efficacy lies in slowing the progression of 
GBM but not in overall survival time increase (Chamberlain 2011). In addition to 
being highly vascularized, the enlarging mass is often associated with a necrotic 
center resulting from hypoxia and lack of nutrients, and there may be interplay 
between insulin signaling and induction of hypoxia mediated by UGFBP2-HIF1α 
interactions (Lin, Liao, and Qutub 2015, Dunn et al. 2012). 
Multiple studies have been focused on immunotherapy as a viable 
treatment modality, with limited positive results as clearly pointed out in a recent 
review (Lim et al. 2018).  Standard clinical approaches of surgery, chemotherapy, 
and radiation are each, and in combination, immunosuppressive. Vaccination 
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and chimeric antigen receptor (CAR) T-cell approaches to GBM reached a wall in 
Phase II and III trials, but oncolytic viruses such as PVS-RIPO show promise in a 
few patients (Bigner 2011, 2017). Injection of PVS-RIPO into the tumor not only 
directly lyses cancer cells, but also alerts the immune system to the tumor’s 
presence (Goetz et al. 2011). Consequently, this approach must be carefully 
monitored to prevent excessive brain swelling (Cavallo 2015). In addition to PVS-
RIPO therapy, other viral therapies targeting GBM are in earlier stages of 
development, such as measles, herpes and zika (Duebgen et al. 2014, 
MayoClinic 2017, Zhu et al. 2017). These viruses preferentially target and kill 
glioblastoma stem cells. Immune checkpoint inhibitors (targeting CTLA-4, PD-L1, 
others) show some promise until the inevitable tumor recurrence.  Many of the 
issues associated with GBM immunotherapy are linked to the well-documented 
local and systemic immunosuppression in patients with the disease, such as 
limited number of tumor infiltrating lymphocytes (TILs) and compromised cell-
mediated immunity (Roszman, Elliott, and Brooks 1991). 
Glioma cells also express high levels of indoleamine 2,3-deoxygenases 
(IDO) that metabolize tryptophan to kynurenine, which drives T-cell suppression 
and immune tolerance (Guastella et al. 2018).  Moreover, kynurenine is a potent 
ligand for the aryl hydrocarbon receptor (AHR), which, when activated, up-
regulates expression of immunosuppressive TGF-β (Gramatzki et al. 2009).  The 
AHR is a member of the basic helix-loop-helix (bHLH-PAS) superfamily of 
proteins and functions as a ligand-activated transcription factor (Gu, Hogenesch, 
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and Bradfield 2000) for multiple responsive gene products. Most notable of these 
genes include phase I and II drug-metabolizing enzymes and transporters 
(Denison et al. 2002, Hu et al. 2007, Nebert et al. 2000, Köhle and Bock 2007).  
Other gene products include proteins associated with cell cycle arrest, such as 
p21, p57, and p27 (Knockaert et al. 2004). 
 
Indirubins and the Aryl Hydrocarbon Receptor (AHR) 
Successful control of glioma cell proliferation (inhibition, induced 
apoptosis), including the targeting of glioma stem cells and promotion of a 
favorable microenvironment to immunologically combat the tumor, is a goal of 
virtually all researchers in the field of brain cancer research.  To that end, a class 
of small molecules, natural indirubin and its derivatives, are being explored as 
promising anti-tumor and immunomodulatory agents (Moon et al. 2006, Kim et al. 
2009). Originally used in Chinese medicine to treat chronic myelogenous 
leukemia, the indigo plant’s active compound has since been identified as 
indirubin and has been synthesized in the lab to create increasingly bioavailable 
derivatives such as indirubin-3’-(2,3 dihydroxypropyl)-oximether (E804) and 7-
bromoindirubin-3'-oxime (7BIO) (Moon et al. 2006). Indirubin is a bis-indole 
alkaloid derived from tryptophan precursors. Indirubin has been shown to inhibit 
angiogenesis in prostate cancer by way of VEGFR2-mediated JAK/STAT3 
pathway disruption (Zhang et al. 2011), decrease inflammatory cytokine signaling 
(interferon gamma and IL6) (Kunikata et al. 2000), and induce cancer cell 
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apoptosis via inhibition of cyclin-dependent kinases (CDKs) (Kim et al. 2009, 
Knockaert et al. 2004, Hoessel, Leclerc, Endicott, Nobel, et al. 1999). 
Additionally, E804 has been shown to inhibit angiogenesis in human umbilical 
vein endothelial cells (HUVECs) in vivo (Shin and Kim 2012), modulate 
inflammatory processes (Babcock, Anderson, and Rice 2013), and inhibit STAT3 
(Nam et al. 2005). The bromo-substituted indirubin 7BIO has been found to 
induce apoptosis in both breast cancer and thyroid carcinoma cell lines (Nicolaou 
et al. 2012). 
In addition to effects on CDK activity, indirubins also bind and activate 
AHR (Adachi et al. 2001, Springs and Rice 2006, Faber et al. 2018, Kawanishi et 
al. 2003), though are metabolized very quickly (Guengerich et al. 2004) by phase 
I enzymes (CYP1A1, CY1B1) induced through AHR activation. However, AHR 
antagonist (e.g. 6, 2′, 4′-trimethoxyflavone – TMF) can inhibit metabolism, and 
spare other desirable functions of these compounds. Likewise, the AHR also 
binds indole-derived compounds found in many cruciferous vegetables (Murray, 
Patterson, and Perdew 2014). It is clear that the AHR plays a key role in a myriad 
of physiological roles; not only of drug metabolism, but also immune regulation, 
organogenesis, mucosal barier function, and cell cycle arrest (Hubbard, Murray, 
and Perdew 2015). AHR-indirubin structure activity relationships (SARs) vary 
depending upon specific indirubin derivative structure and bioavailability 
(Blažević et al. 2015). Further elucidation of how AHR versus CDK activity 
relates to indirubin derivatives is a promising avenue of GBM research. The two 
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derivatives of indirubin, E804 and 7BIO, have been chosen for their known anti-
inflammatory and potential anti-tumor properties (Kim et al. 2009, Moon et al. 
2006, Nicolaou et al. 2012, Shin and Kim 2012). While traditional treatment 
options for GBM should not be abandoned, the diversity of cancer diagnoses 
requires a multi-tier treatment approach. Additional complementary treatment 
options for GBM are needed. Less toxic compounds that can modulate the tumor 
immune and inflammatory environment are promising drug candidates that may 
displace current strategies such as carmustine-laden wafers. 
 
The Unfolded Protein Response (UPR) 
The endoplasmic reticulum (ER) is responsible for synthesizing, modifying 
and folding proteins within the cell. Proteostasis within the ER is maintained by a 
variety of factors and managed by a multipronged pathway termed the unfolded 
protein response (UPR), which surveys and responds to misfolded or unfolded 
proteins within the cellular environment (Hetz, Chevet, and Oakes 2015). ER 
stress may be induced by a multitude of reasons, including pathophysiologies 
such as tumor development (Vandewynckel et al. 2013). If proteostasis is 
disrupted, one or all three branches of the UPR can be activated to deal with the 
accumulation of misfolded proteins. The overlapping redundancies built into the 
UPR pathway ensure restoration of normal cellular function, or if unable to 
restore homeostasis, induction of apoptosis. If too many misfolded proteins are 
detected, translation is halted and misfolded proteins simultaneously destroyed. 
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Additionally, chaperone proteins are increased to help with proper folding of other 
proteins (Obacz et al. 2017).  
The three major arms activated within the UPR are regulated by the 
membrane bound sensors protein kinase R–like ER kinase (PERK), inositol-
requiring enzyme 1α (IRE1) and activating transcription factor 6α (ATF6). These 
can be distinctively active, but are also commonly co-regulated. Considered the 
master regulator of the UPR, glucose-regulated protein 78 (GRP78) keeps these 
three transcription factors in an inactive state under normal conditions. During ER 
stress, GRP78 will dissociate from PERK, IRE1, and/or ATF6, and tag the 
misfolded protein, signaling for the pathway to commence (Chaudhari et al. 
2014). Therefore, GRP78 supports cell survival by inhibiting UPR-induced 
apoptosis. GRP78 is upregulated in some chemoresistant cancers, and thus is 
associated with chemo-resistance (Roller and Maddalo 2013). 
Although not wholly understood, the UPR appears to play a supporting 
role in tumorigenesis and tumor progression in many cancer types, including 
Glioblastoma Multiforme (GBM) (Ma and Hendershot 2004). Tumorigenesis 
induces ER stress, which if prolonged can further aid in tumor progression. Due 
to mutation, hypoxic conditions, glucose deprivation, low pH, and rapid growth, 
tumor cells are exposed to many factors that heighten the risk of protein 
misfolding. These stressors, combined with increased protein requirements, lead 
to induction of the UPR (Ma and Hendershot 2004). The adaptive healing and 
anti-apoptotic responses of the UPR are first induced in order to process the 
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accumulation of misfolded proteins. If unsuccessful, later responses may lead to 
induction of apoptosis. However, tumors appear able to exploit these stress 
response pathways to benefit from initial pathway protective mechanisms, while 
avoiding later-stage apoptosis (Luo and Lee 2013). Constitutive UPR activation 
has been reported in many tumors, including GBM. Specifically the IRE1 and 
PERK arms of the UPR have been implicated in GBM growth and progression 
(Doultsinos et al. 2019). Prolonged, chronic activation of the UPR pathways has 
been implicated in tumor progression, thus targeted down-regulation of certain 
UPR-related genes is a likely therapeutic target for GBM and other cancers.  The 
increase in UPR activity during glioma initiation and progression provides a fresh 
avenue of exploration for potential cancer therapeutics. It is my hope that new 
therapeutic targets may be identified from work such as described here.  
UPR regulation is investigated herein by E804. Indole compounds are 
documented regulators of the UPR system (Chakraborty et al. 2016). 
Additionally, the bis-indole alkaloid compound indirubin has been well studied for 
its immune-modulatory properties (Qi, Li, and Li 2017, Cheng and Merz 2016). 
Synthetic indirubins such as E804 used herein are designed to increase 
bioavailability via substitution group alterations. Certain indirubin derivatives are 
posited to have neuro-protective effects via down-regulation of apoptosis-
inducing genes in the UPR pathway such as CHOP (Kosuge et al. 2017). 
Indirubin-induced CHOP down-regulation may work via inhibition of glycogen 
synthase kinase 3 (GSK-3) (Meares et al. 2011). Additionally, GSK-3 is a major 
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regulator of numerous and diverse pathways. Dysregulation of these pathways 
are implicated in many disease types, including cancer (Mancinelli et al. 2017). 
GSK-3 regulates the STAT3 pathway, which is implicated in glioma development 
(Ganguly et al. 2018) and which has been found to be down-regulated by E804 
treatment in prior work (cite my paper). 
Much of the UPR pathway remains unexplored with regards to indirubin 
treatment. Herein I explore the effect E804 treatment on UPR pathway 
modulation in two GBM cell lines that show high, yet variable, AHR expression. 




While GBM are astrocyte in cellular origin, a malignant GBM tumor can be 
comprised of up to 50% microglia (Hambardzumyan, Gutmann, and Kettenmann 
2016). Microglia are CNS macrophages that are present under normal 
circumstances in the brain and spine, but have been found at higher percentage 
in association with low-grade gliomas. Additionally, during a traumatic brain event 
such as brain cancer other immune cells can cross the blood brain barrier. 
Monocyte-derived macrophages have also been found to associate with glioma 
tumors at higher percentages (15-30%) than in normal non-neoplastic brains (10-
15%) (Simmons et al. 2011). 
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This influx of macrophages may be due to the fact that macrophages and 
microglial are important to tumor survival and growth. Often referred to as 
glioma-associated macrophages (GAMs), they can assist in neo-vascularization 
and general tumor growth (Hambardzumyan, Gutmann, and Kettenmann 2016). 
Even in normal tissue macrophages are heterogeneous; consequently GAMs 
follow more than just one phenotype, according to in vitro studies (Kennedy et al. 
2013). Depending on what cytokine and cognate stimulation the GAM receives, 
these macrophages will express different cellular markers that can be used to 
polarize them into different phenotypes (M1 and M2). The M1 phenotype is a T-
helper 1 (Th1) driven macrophage. M1 cells are polarized by LPS and IFN-
gamma, and release pro-inflammatory cytokines such as IL-12, IL-23, and iNOS 
(Hambardzumyan, Gutmann, and Kettenmann 2016, Bygd, Forsmark, and Bratlie 
2014). By contrast, the M2 phenotype is a T-helper 2 (Th2) driven macrophage, 
that can be further divided into M2a, M2b, and M2c subsets. In general, M2 cells 
are polarized by IL-4, IL-10 and IL-13, and release anti-inflammatory cytokines 
such as IL-10, IL-1Rα, TGF- β, and TNF-α (Hambardzumyan, Gutmann, and 
Kettenmann 2016, Bygd, Forsmark, and Bratlie 2014). 
Although the easy dichotomy of this classification is somewhat misleading 
given the plasticity of myelomonocytic cell populations, the general categorization 
may be helpful in directing new lines of GBM treatment research. Previous 
studies suggest that the M2 phenotype correlates with increased glioma growth 
(Feng et al. 2015). It has also been demonstrated that inhibition of M2-like 
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macrophages can slow glioma growth (Pyonteck et al. 2013). It is possible that 
by inducing a switch from M2 to M1 polarization, a new immunotherapy for GBM 
may be identified (Prinz and Priller 2014). 
 
 
Wnt pathway crosstalk with TLR and AHR pathways 
The Wingless-related integration site (Wnt) pathway plays a major role in 
embryonic development, cell proliferation, cell migration, and tissue homeostasis. 
Abberant Wnt signaling has been implicated in human colorectal, breast, 
pancreatic ductal adenocarcinoma (PDAC), endometrial, and brain cancers 
(Zhan, Rindtorff, and Boutros 2017). Due to demonstrated tumor promoting 
characteristics in many cancer types including GBM, members of the Wnt 
pathway are logical therapeutic targets (Suwala et al. 2016, McCord et al. 2017).   
In GBM, Wnt activation has been linked to radio-resistance in vivo (Kim et 
al. 2012), glioma stem cell (GSC) persistence (Wu et al. 2017), and proliferation, 
survival, and clonogenicity of GBM cells (Kahlert et al. 2015). Not only is Wnt 
implicated in GBM progression, elevated Wnt proteins aid in microglial 
recruitment and perhaps M2 polarization (Matias et al. 2019), thus contributing to 
GBM tumor expansion via immune cell reprogramming. Through dispatch of Wnt 
signals, M2 macrophages may engage in matrix remodeling that could have 
significant ramifications for GBM tumor structure. Conversely, inhibition of Wnt 
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signaling can prevent M2 macrophage polarization that would otherwise be 
induced by IL-4 or TGF-β (Feng et al. 2018).  
Of special relevance to the body of work presented herein, the Wnt 
pathway is functionally connected to both Toll-Like Receptor (TLR) (Casili et al. 
2018, Zolezzi and Inestrosa 2017) and AHR (Mathew, Simonich, and Tanguay 
2009, Procházková et al. 2011) signaling. As master regulator of inflammation, 
NF-κB provides a link between pathways involved with innate immune system 
inflammatory signaling, such as the Wnt and TLR pathways. Particularly 
important in neuroinflammatory diseases such as Alzheimer’s disease (AD) or 
GBM, inflammatory signaling mediated by NF-κB is a central component in brain 
dysregulation. Compounded by the high percentage of innate immune cells such 
as macrophages present in the GBM environment, the TLR pathway is an 
important target with regards to immunomodulation. Not only do Wnt and TLR 
inflammatory signaling overlap; crosstalk has been demonstrated between Wnt 
and AHR pathways as well. Both the AHR and Wnt pathway are evolutionarily 
conserved and important in normal development (Schneider, Branam, and 
Peterson 2014). AHR activation has been shown to antagonize the Wnt pathway 
in multiple models. Evidence for crossover signaling between Wnt and the AHR 
has been found in zebrafish via R-spondin1 (Mathew et al. 2008), in mouse 
embryonic stem cells via binding of dioxin (Wang et al. 2015), in mouse 
hepatoma cells via the cyp1a1 promoter (Schulthess et al. 2015), and beyond. 
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Thus, targeting of the AHR in GBM may induce modulation of other key 
pathways that aid in brain development and inflammatory regulation.  
 
The model 
LN-18 and T98G cell lines (ATCC), initially collected from grade IV 
astrocytomas in Caucasian males ages 65 and 61 respectively, were chosen for 
their sensitivity to indirubin compounds, such as E804, due to high expression of 
the aryl hydrocarbon receptor (AHR) (Gramatzki et al. 2009). To date, both cell 
lines have been used extensively in both brain cancer and ER stress research 
(Weatherbee, Kraus, and Ross 2016, Nguyen et al. 2019). Both cell lines are 
documented as susceptible to ER stress, especially via PERK signaling (Jia et al. 
2010). Therefore, LN-18 and T98G cell lines are good models to study the 
potential neuro-protective effects of indirubins via immunomodulation and 
alleviation of ER stress.  
Not only do these cell lines have an active protein stress response, they 
also express high levels of tumor suppressor genes that respond to genotoxic 
stress such as p53 and p21. T98G cells typically have higher levels of p53 
protein, as they are homozygous mutant at 237, while LN-18 cells are 
heterozygous mutant at 238. Both cell lines express high levels of p21 and do not 
express p16 (Weller et al. 1998). T98G cells have higher protein levels of BCL-2 
apoptotic family proteins, including BCL-2, MCL-1, BCL-X, and BAX. Additionally, 
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the LN-18 cell line is generally more sensitive to drug-induced cytotoxicity than 
the T98G line (Weller et al. 1998).  
 The peripheral blood monocyte cell line THP-1 (ATCC) was initially 
collected from a 1-year old male with acute monocytic leukemia. THP-1 cells 
were chosen for their common use as differentiated macrophages in 
inflammation and cancer studies. The THP-1 cell line is an established model 
mimicking monocyte-derived macrophages in vitro. Additionally, THP-1 
macrophages differentiated with PMA are easily polarized along the continuum of 
M1 and M2 phenotypes (Wang et al. 2014, Genin et al. 2015). Stimulation of 
THP-1 monocytes and macrophages with LPS also demonstrates this cell line is 
an ideal candidate for studying inflammation and immunomodulation (Chanput et 
al. 2010, Robertson et al. 2015, Wang, Pham, and Kim 2018).    
 
Conclusion 
The goal of this research is to characterize the effects that E804 and 7BIO 
have on the inflammatory environment of human GBM and THP-1 cell lines as 
mediated by the AHR pathway. The two derivatives of indirubin, E804 and 7BIO, 
have been chosen for their known immunomodulatory properties (Kim et al. 
2009, Moon et al. 2006, Nicolaou et al. 2012, Shin and Kim 2012). AHR 
antagonist TMF will be used to investigate the impact of indirubin treatments on 
the AHR pathway specifically. While current avenues of GBM research hold 
promise, complementary treatment options for GBM are needed. Small 
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molecules like indirubin that can target inflammatory signaling, UPR signaling, or 
influence immune cell recruitment in the tumor microenvironment are promising 
drug candidates. To my knowledge, the studies proposed herein are the first as 
of this writing to explore the mechanisms of the AHR signaling pathway upon 
indirubin binding in GBM in vitro models. In addition to the furtherance of the 
neuro-onocology body of knowledge, elucidation of indole-AHR signaling in GBM 
will benefit the field of immunotoxicoogy. Importantly, the questions outlined 
herein will help to better understand AHR-targeted therapy, and perhaps outline 
future GBM drug development and inquiry. 
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MODULATION OF GLIOMA-INFLAMMATION CROSSTALK 
PROFILES IN HUMAN GLIOBLASTOMA CELLS BY INDIRUBIN-3’-
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Indirubins E804 (indirubin-3’-(2,3 dihydroxypropyl)-oximether) and 7BIO (7-
Bromoindirubin-3'-oxime) are synthetic derivatives of natural indirubin, the active 
compound in Danggui Longhui Wan, a traditional Chinese remedy for cancer and 
inflammation. Herein, I explore E804 and 7BIO for their potential to modulate key 
pro-inflammatory genes and cytokines in LN-18 and T98G glioblastoma cells.  
High grade gliomas typically secrete large amounts of inflammatory cytokines 
and growth factors that promote tumor growth in an autocrine fashion. 
Inflammation is emerging as a key concern in the success of new treatment 
modalities for glioblastomas. Studies indicate that select indirubin derivatives 
bind and activate signaling of the AHR pathway, as well as inhibit cyclin-
dependent kinases and STAT3 signaling.  AHR signaling is involved in 
hematopoiesis, immune function, cell cycling, and inflammation, and thus may be 
a possible target for glioma treatment. To determine the significance of the AHR 
pathway in LN-18 and T98G glioma inflammatory profiles, and on the effects of 
E804 and 7BIO on these profiles, I used 6,2′,4′-trimethoxyflavone (TMF), a 
putative selective AHR antagonist. It was confirmed that E804 and 7BIO 
activates the AHR leading to cyp1b1 expression, and that TMF antagonizes 
expression. I then employed a commercial cancer inflammation and immunity 
crosstalk qRT-PCR array to screen for anti-inflammatory related properties. TMF 
alone inhibited expression of ifng, ptsg2, il12b, tnfa, il10, il13, the balance 
between pd1 and pdl1, and even expression of mhc1a/b. E804 was very potent 
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in suppressing many pro-inflammatory genes, including il1a, il1b, il12a, ptgs2, 
tlr4, and others. E804 also affected expression of il6, vegfa, and stat3.  
Conversely, 7BIO induced cox2, but suppressed a different selection of pro-
inflammatory genes including nos2, tnfa, and igf1. Secretion of IL-6 protein, an 
iconic inflammatory cytokine, was decreased by E804. VEGF (vascular 
endothelial growth factor) protein secretion was upregulated by 7BIO, yet 
downregulated by E804 and E804 plus TMF. Thus, E804 is both an AHR ligand 
and regulator of important pro-inflammatory cytokines such as IL-6 and 
oncogene STAT3, among others. These results point to the use of E804 and 
TMF in combination as a promising new treatment for glioblastoma. 
 
Key words: Glioblastoma multiforme, Aryl hydrocarbon receptor, Indirubin, E804, 7BIO, 
Inflammation, Immunomodulation.	  
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1.0.  INTRODUCTION 
	
	
Primary brain cancer and other central nervous system (CNS) cancers 
account for an estimated 16,830 deaths in 2018 in the US alone (Siegel, Miller, 
and Jemal 2018). Out of all brain and CNS malignancies, 30% are gliomas 
(National Brain Tumor Society , Goodenberger and Jenkins 2012). Of these 
gliomas, glioblastoma multiforme (GBM) (WHO grade IV) is the most aggressive 
and lethal subset (Holland 2000). Found mainly in the cerebral hemispheres, 
GBM may arise from astrocytes, but other cell types may contribute as well, 
including neuronal and oligodendrocyte precursors (Zong, Verhaak, and Canoll 
2012, Zong, Parada, and Baker 2015, Alcantara Llaguno and Parada 2016), 
which may determine the origin and nature of glioma stem cells (Jackson, 
Hassiotou, and Nowak 2014).  GBM can metastasize to any area of the brain or 
spinal cord (American Brain Tumor Association 2014, Alifieris and Trafalis 2015). 
Extra-CNS metastasis is extremely rare, but has been documented in a few 
cases (Hamilton et al. 2014). By the time of diagnosis, the highly malignant mass 
can be large, causing symptoms such as headache, nausea, vomiting, 
drowsiness, cognitive and personality changes, and seizures (Omuro and 
DeAngelis 2013). Median survival with treatment is only 14.6 months; fewer than 
30% of patients survive 2 years (American Brain Tumor Association 2014, 
Alifieris and Trafalis 2015). 
Glioma cells express high levels of indoleamine 2,3-deoxygenases (IDO) 
that metabolize tryptophan to kynurenine, which drives T-cell suppression and 
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immune tolerance (Guastella et al. 2018).  Moreover, kynurenine is a potent 
ligand for the aryl hydrocarbon receptor (AHR), which, when activated, 
upregulates expression of TGF-β, which is immunosuppressive (Gramatzki et al. 
2009).  The AHR is a member of the basic helix-loop-helix (bHLH-PAS) 
superfamily of proteins and functions as a ligand-activated transcription factor 
(Gu, Hogenesch, and Bradfield 2000) for multiple responsive gene products. 
Most notable of these genes include phase I and II drug-metabolizing enzymes 
and transporters (Denison et al. 2002, Hu et al. 2007, Nebert et al. 2000, Köhle 
and Bock 2007).  Other gene products include proteins associated with cell cycle 
arrest, such as p21, p57, and p27 (Knockaert et al. 2004).  The AHR is also 
involved in the polarization of T-cells towards T-regs, furthering the 
immunosuppressive tumor microenvironment, and influences the polarization of 
macrophages (Gabriely and Quintana 2019). AHR activation by tumor-derived 
kynurenine also suppresses nfkb1 activation in glioma-associated macrophages, 
and promotes ccl2 and ccr2 expression, thereby driving these macrophages 
towards a M2 phenotype (Takenaka et al. 2019).   
Mechanistically, there is evidence that signal transducer and activator of 
transcription 3 (STAT3), may be a key mediator of both glioma cell proliferation 
and negative effects on the tumor microenvironment, namely suppressing GAMs, 
while promoting T-regs and myeloid-derived suppressor cells (Chang et al. 
2017).  Stat3 is constitutively activated in the majority of GBM patients, and the 
level of expression correlates well with histological grade and prognosis (Abou-
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Ghazal et al. 2008, Matsebatlela et al. 2015, Tu et al. 2011, Ganguly et al. 2018). 
Moreover, glioma cells actively secrete growth factors to activate and maintain 
expression of stat3 in glioma stem cells (Almiron Bonnin et al. 2017). Considering 
the key role of STAT3 in glioma growth and effects on the microenvironment, 
therapies targeting STAT3 should be of high priority. One small molecule 
(ibrutinib) inhibitor of bone marrow and X-linked (BMX) non-receptor tyrosine 
kinase that is linked to stat3 upregulation in glioma stem cells is already receiving 
attention (Shi et al. 2018).   
Natural indirubin and its derivatives have been explored as promising anti-
tumor and immunomodulatory agents (Moon et al. 2006, Kim et al. 2009). 
Originally used in Chinese medicine to treat chronic myelogenous leukemia, the 
indigo plant’s active compound has since been identified as indirubin and has 
been synthesized in the lab to create increasingly bioavailable derivatives such 
as indirubin-3’-(2,3 dihydroxypropyl)-oximether (E804) and 7-bromoindirubin-3'-
oxime (7BIO) (Moon et al. 2006). Indirubin is a bis-indole alkaloid derived from 
tryptophan precursors. Indirubin has been shown to inhibit angiogenesis in 
prostate cancer by way of VEGFR2-mediated JAK/STAT3 pathway disruption 
(Zhang et al. 2011), decrease inflammatory cytokine signaling (interferon gamma 
and IL6) (Kunikata et al. 2000), and induce cancer cell apoptosis via inhibition of 
cyclin-dependent kinases (CDKS) (Kim et al. 2009, Knockaert et al. 2004, 
Hoessel, Leclerc, Endicott, Nobel, et al. 1999, Babcock, Anderson, and Rice 
2013). E804 has also been shown to inhibit angiogenesis in human umbilical vein 
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endothelial cells (HUVECs) in vivo (Shin and Kim 2012), has potent anti-
inflammatory properties (Babcock, Anderson, and Rice 2013), and inhibits 
STAT3 (Nam et al. 2005). The bromo-substituted indirubin 7BIO has been found 
to induce apoptosis in both breast cancer and thyroid carcinoma cell lines 
(Nicolaou et al. 2012). 
In addition to their effects on CDK activity, indirubins also bind and 
activate AHR (Adachi et al. 2001, Springs and Rice 2006, Faber et al. 2018, 
Kawanishi et al. 2003), though are metabolized very quickly (Guengerich et al. 
2004) by phase I enzymes induced through AHR activation. However, AHR 
antagonists, such as 6, 2′, 4′-trimethoxyflavone (TMF) can inhibit metabolism, 
and spare other desirable functions of these compounds. In the study described 
herein, indirubin derivatives E804 and 7BIO were chosen for their known anti-
inflammatory and potential anti-tumor properties (Kim et al. 2009, Moon et al. 
2006, Nicolaou et al. 2012, Shin and Kim 2012). Each compound, alone and in 
the presence of TMF, were examined for their effects on inflammatory profiles of 
two human glioblastoma cell lines, LN-18 and T98G, each differing in patient 
origin and in level of basal expression of the AHR (Gramatzki et al. 2009).  
Indirubin E804 was superior to 7BIO as an anti-inflammatory agent, and was 
shown to be a potent ligand for the AHR, though TMF was able to inhibit this 
effect. While traditional treatment options of GBM should not be abandoned, 
additional complementary treatment options for GBM are needed. Less toxic 
compounds that can modulate the tumor immune and inflammatory environment 
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are promising drug candidates that may displace current strategies like 
carmustine-laden wafers. 
2.0.  MATERIALS AND METHODS   
	
	
2.1. Chemicals:  Indirubin-3’-(2,3 dihydroxypropyl)-oximether (E804) and 7-
Bromoindirubin-3'-oxime (7BIO) were obtained from Alexis Biochemical (CA, 
USA). The AHR antagonist 6,2’,4’-trimethoxyflavone (TMF) was purchased from 
Sigma-Aldrich (MO, USA). Stock solutions at 10-2 M were prepared by 
solubilizing compounds in dimethyl sulfoxide (DMSO, Corning, NY, 
USA). Chemical structures for E804, 7BIO, and TMF are shown in Figure 1.  
  
 
Figure 1. Chemical structures for a) Indirubin-3’-(2,3 dihydroxypropyl)-oximether (E804), 
b) 7-Bromoindirubin-3'-oxime (7BIO), and c) 6, 2′, 4′-trimethoxyflavone (TMF). 
	
2.2.  Cell culture:  Human Glioblastoma Multiforme (GBM) cell lines, LN-18 
(ATCC CRL-2610) and T98-G (ATCC CRL-1690), were obtained from ATCC 
(VA, USA) and cultured using Dulbecco’s Modified Eagle’s Medium (DMEM, 












heat-inactivated fetal bovine serum (FBS) with iron (Hyclone, USA), 
20 mM HEPES, 10 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 
110 μg/ml sodium pyruvate, 1% non-essential amino acids (100 × stock), 4.5 g/l 
glucose, and 1.5 g/l of NaHCO3, each from Sigma (Sigma Aldrich, MO, USA). 
Cells were typically grown and maintained at 37 °C with 5% CO2 in Corning 
75 cm2 culture flasks. 	
  	
2.3. Effects of E804 and 7BIO on cyp1b1 and stat3 mRNA expression:  
 LN-18 and T98G cells were seeded in 6-well plates (Corning Primaria™, NY, 
USA) at 2 x 106 cells per well in 2 ml, and allowed to adhere for 4 h. Wells were 
then treated with 10 µM E804 or 7BIO, with 0.1% DMSO as the carrier control, 
and with/without 10 µM TMF, in a total of 3 ml complete medium per well. Six and 
24 h post-exposure, supernatants were removed from the wells and stored at -20 
ºC for later cytokine analysis. The experiment was repeated three times. 
Messenger RNA was extracted using RNAzol (Molecular Research Center, OH, 
USA) according to the manufacturer’s protocol. Complementary DNA was 
synthesized using qScript cDNA Supermix (Quantabio, MA USA). Each 
experiment was repeated three times. Gene expression was analyzed by 
quantitative real-time PCR with a BioRad iC5 detection system, RT2 SYBR 
green/fluorescein master mix (Qiagen), and primer sets designed using 
Integrated DNA Technology (IDT) software, and validated prior to use (Table 1). 
The quantity of cyp1b1 and stat3 mRNA was expressed as fold-changes in gene 
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expression compared to gapdh. For data analysis, the ΔΔCt method was used. 
Expression data were compared between treatment groups using ANOVA, 
followed by a Bonferroni's post-test using GraphPad5 statistical package. 
 




2.4. Focused commercial RT-qPCR Super-Arrays for cancer inflammation 
and immunity crosstalk:  LN-18 and T98G cell lines were grown and treated 
with E804, 7BIO, with/without TMF, or DMSO carrier control as described for RT-
qPCR as above. RNAzol (Molecular Research Center, OH, USA) was added to 
each well and the mixture homogenized by gentle pipetting several times. This 
homogenate was passed to the second experimental exposure, and then to the 
third to pool all three treatments. mRNA was extracted according to 
manufacturer’s instructions (Molecular Research). After collecting mRNA from 
each tube, genomic DNA contamination was removed using elimination mixture 
supplied by the manufacturer, and first strand cDNA synthesis was carried out 
using the RT2 Easy First Strand Kit (Qiagen) as described by the 
manufacturer.  A predesigned Cancer Inflammation & Immunity Crosstalk 







Gapdh NM_001256799 57 105
Stat3 NM_003150 52 138
Cyp1b1 NM_000104 52 115
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Profiler™ array of 96 genes was purchased from Qiagen Corporation (cat 
# PAHS-181Z) for use with RT2 Real-Timer SYBR Green/fluorescein qPCR 
master mixes purchased from the same supplier. Specific methods followed 
those suggested by the manufacturer. RT-qPCR was performed on a BioRad iQ5 
real-time PCR detection system. For data analysis, the ΔΔCt method was used; 
for each gene fold-changes were calculated as difference in gene expression 
between untreated controls and treated cell cultures. Data were gathered and 
interpreted using software provided by Qiagen. Details on methods have been 
previously published (Matsebatlela et al. 2015, Babcock, Anderson, and Rice 
2013). 
 	
2.5. Enzyme-linked immunosorbent assay (ELISA): An enzyme-linked 
immunosorbent assay (ELISA) was used to quantify interleukin-6 (IL-6) and 
vascular endothelial growth factor (VEGFA) secreted by LN-18 and T98G cells 
following treatment at 6 and 24 h. Supernatants from cells treated with E804 or 
7BIO, carrier control, and with or without TMF for qPCR studies were used as the 
source. A commercially available ELISA kit from BioLegend (CA, USA) was used 
for both IL-6 and VEGFA cytokine assays. Three different experiments were 
examined independently. Cytokine levels were compared between treatment 








3.1.      E804 and 7BIO induce expression of cyp1b1 and stat3 mRNA	
Cyp1b1 induction was used as a marker for relative AHR activity in LN-18 and 
T98G glioma cell lines after E804 and 7BIO treatment at 6 h and 24 h post-
exposure. There was no response to either indirubin in LN-18 cells at 6 h, but by 
24 h cyp1b1 expression was 20-fold higher in E804 treated cells over the control, 
and was slightly less induced by 7BIO (Figure 2). TMF moderately induced 
cyp1b1 in LN-18 cells at both 6 h and 24 h post-exposure. TMF also antagonized 
the AHR activity of E804, but not that of 7BIO. In contrast, 7BIO induced cyp1b1 
at 6 h post-exposure in T98G cells, but not by 24 h, while it took 24 h for E804 to 
induce expression. TMF antagonized cyp1b1 induction by both E804 and 7BIO in 
T98G cells.  Stat3 mRNA expression in LN-18 cells was enhanced by 7BIO, but 
not by E804 at 6 h exposure, and TMF did not modify these responses (Figure 
3).  By 24 h exposure the combination of 7BIO and TMF increased stat3 
expression.  In T98G cells, none of the treatments affected stat3 expression at 6 
h exposure.  By 24 h exposure, 7BIO induced stat3 expression, and this effect 
was not modified by TMF co-exposure.  In comparison to E804, 7BIO induces 





Figure 2. The effects of E804 or 7BIO, and/or TMF, on expression of cyp1b1. Data are 
represented as fold change compared to the control and normalized against house-
keeping reference gapdh. All compounds treated at 10 μM. Gene expression in a, c) the 
LN-18 cell line and b, d) the T98G cell line, for 6 h (a and b) or 24 h (c and d). Data 
represent the mean fold expression + S.E. of three different experiments. (**) indicates p 



































































































































































Figure 3. The effects of E804 or 7BIO, and/or TMF, on expression of stat3. Data are 
represented as fold change compared to the control and normalized against house-
keeping reference gapdh.  All compounds treated at 10 μM. Gene expression in a, c) the 
LN-18 cell line and b, d) the T98G cell line, for 6 h (a and b) or 24 h (c and d). Data 
represent the mean fold expression + S.E. of three different experiments. (*) indicates p 
































































































































































3.2.  Effects of treatments on cancer-inflammation cross-talk arrayed genes 
Broadly, E804 treatment suppressed the expression of most pro-inflammatory 
genes, including cytokines il1a and il1b, il12, nos2, and ifng in LN-18 cells, with 
7BIO having less of an effect (Table 2). Of particular note, E804 suppressed egfr, 
a key treatment target for some glioma subtypes. One of the most profound 
effects was that both compounds greatly suppressed csf2 and csf3 expression.  
Pd1 and pdl1 were suppressed by both indirubins, and especially in the presence 
of the AHR antagonist TMF. The combination of either E804 or 7BIO and TMF 
suppressed the expression of tlr2 to a great degree at both 6 and 24 h. With a 
few of the inflammatory genes, treatment with TMF alone was suppressive in 
terms of gene expression. Of note, E804 treatment suppressed the expression of 
MHC-1 genes, as did TMF treatment. 
 T98G cells were more sensitive to the anti-inflammatory effects of E804 
and 7BIO than LN-18 cells (Table 3). Most of the pro-inflammatory genes were 
suppressed, except that il12b, il23a, and nos2 were induced. Treatment with 
E804 increased the expression of il10 and il13 at 24 h. However, pdl1 is still a 
likely target, as is ctla4 when in the presence of an AHR antagonist and either 
E804 or 7BIO. Of note, igf1 expression was greatly impacted by both indirubins, 
as well as TMF, at 24 h. Unlike the effects of E804 and TMF on mhc1a/b 
expression invLN-18 cells, there was little effect on mhc1a/b expression in T98G 
cells. Also, in contrast to LN-18 cells, EGFR was not targeted by treatments. 
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Table 2. Select genes from commercial Human Cancer Inflammation and Immunity 
Crosstalk™ array displaying genes associated with inflammation, growth, signal 
transduction, and antigen presentation. All compounds treated at 10 μM. Treatments 
were compared to 0.1% DMSO as carrier control. LN-18 cells were treated for 6 h or 24 
h, and triplicate samples pooled before mRNA extraction. Data represented as fold 
change compared to the appropriate time-point control and normalized against house-




E804 7BIO TMF E804 + TMF
7BIO + 





Chemokine ligand 2 NM_002982 CCL2 -1.57 -1.19 -2.94 -4.09 -2.46 -6.84 -1.36 -2.89 -1.89 -6.13
Chemokine ligand 10 NM_004591 CCL20 -6.30 -2.79 -1.25 1.68 1.40 -9.00 -4.42 -1.38 2.69 -2.97
Cyclooxygenase 2 NM_000963 COX2 1.64 2.25 -3.24 -1.48 2.69 -1.29 2.16 -5.27 -2.47 3.10
Interferon gamma NM_000619 IFNG 1.13 -1.01 -4.50 1.00 -23.14 -2.14 -2.49 -4.44 -25.21 -3.51
Interleukin 1α NM_000575 IL1A -4.37 1.58 1.93 -2.91 3.32 -4.07 1.03 2.55 -4.29 -1.80
Interleukin 1β NM_000576 IL1B -2.84 1.18 2.70 1.76 8.33 -19.07 1.75 1.92 3.54 2.36
Interleukin 2 NM_000586 IL2 1.13 -1.01 1.00 -2.06 -1.73 -2.14 1.39 -1.08 -1.81 7.12
Interleukin 6 NM_000600 IL6 1.49 1.26 -1.17 2.73 1.84 -5.89 1.50 -2.43 1.05 -3.11
Interleukin 12α NM_000882 IL12A -10.43 -3.32 1.11 1.21 -2.43 -5.23 1.17 3.36 1.52 3.08
Interleukin 12β NM_002187 IL12B 1.13 -1.01 -12.23 14.10 -13.09 -2.14 -2.49 -2.43 8.54 -1.55
Interleukin 23α subunit p19 NM_016584 IL23A 1.13 -1.01 -1.61 -16.70 1.52 1.69 2.58 1.43 2.35 9.22
Inducible nitric oxide synthase NM_000625 INOS -4.49 -4.26 -1.85 2.90 -1.55 4.00 -2.29 1.56 13.85 5.98
Toll like receptor 4 NM_138554 TLR4 -7.23 -2.30 1.02 -2.55 -1.85 -6.52 1.08 1.61 -6.51 -1.20
Tumor necrosis factor α NM_000594 TNFA 3.52 -1.81 -6.92 10.94 -1.37 -2.99 -3.48 -3.07 2.50 -1.76
Cytotoxic T-lymphocyte-associated protein 4 NM_005214 CTLA4 1.13 -1.01 1.00 -27.66 -13.38 -2.14 -2.49 -14.46 -5.26 -4.57
Chemokine ligand 5 NM_002994 CXCL5 1.13 -1.01 -2.06 -6.53 1.04 -2.14 -2.49 -2.19 1.05 1.99
Chemokine ligand 12 NM_000609 CXCL12 -1.78 -4.02 -4.00 -7.85 -47.00 -5.57 1.04 -3.03 -5.48 -10.16
Indoleamine 2,3-dioxygenase 1 NM_002164 IDO1 1.94 -1.01 2.95 4.78 7.03 -4.03 1.46 -1.04 -2.08 11.98
Interleukin 4 NM_000589 IL4 5.45 -1.01 2.06 3.23 1.43 -2.14 -2.49 3.44 2.46 8.36
Interleukin 8 NM_000584 IL8 -1.12 2.03 2.31 1.46 3.51 -8.52 -3.10 -13.69 1.43 -8.83
Interleukin 10 NM_000572 IL10 1.13 -1.01 -1.74 -11.76 1.14 -2.14 -2.49 -2.15 -1.09 2.81
Interleukin 13 NM_002188 IL13 -1.95 -1.78 -3.72 -1.12 -1.90 -1.46 -2.38 -1.95 -1.89 3.83
Programmed cell death 1 NM_005018 PD1 1.13 -1.01 -6.96 1.00 1.00 -2.14 -2.49 1.00 1.00 -35.02
PD ligand 1 NM_014143 PDL1 -3.28 -3.80 2.94 1.02 1.02 -6.99 -2.10 3.12 -1.32 -1.06
Transforming growth factor β1 NM_000660 TGFB1 -1.70 -1.66 1.78 1.60 1.97 -1.16 -1.09 1.32 -1.09 5.73
Epidermal growth factor NM_001963 EGF -3.72 1.16 -1.71 -5.83 -2.16 1.24 2.42 4.46 2.89 5.49
EGF receptor NM_005228 EGFR -3.39 -1.61 1.31 -1.58 1.43 -5.84 1.04 1.45 -4.38 2.98
Insulin like growth factor 1 NM_000618 IGF1 -1.79 -1.41 2.65 -1.71 2.57 -1.14 2.15 6.51 1.53 14.92
IL-15 NM_000585 IL15 -2.27 1.52 -1.20 -2.81 -1.48 -2.71 1.15 -1.03 -6.58 1.16
Secreted phosphoprotein 1 NM_000582 SPP1 -1.32 -1.24 1.57 1.29 2.20 -1.10 -1.63 1.36 1.33 -86.08
Granulocyte macrophage CSF-2 NM_000758 CSF2 -2.28 -2.12 -1.19 -1.07 -2.04 -11.63 -3.78 -3.68 -1.32 -5.01
Granulocyte CSF-3 NM_000759 CSF3 -20.76 -1.91 1.17 -1.88 2.07 -3.49 -3.20 -1.28 2.45 1.18
Signal transducer and activator of transcription 3 NM_003150 STAT3 -1.44 -1.76 1.71 1.32 1.73 -3.50 -1.30 1.23 -1.95 1.77
Toll like receptor 2 NM_003264 TLR2 -1.87 -2.14 -1.95 -115.20 -7.94 -3.06 1.85 -1.12 -254.96 -51.76
Toll like receptor 3 NM_003265 TLR3 -6.96 -2.05 3.38 2.30 2.94 -12.63 1.72 3.97 -1.94 8.19
Major histocompatibility complex, class I, A NM_002116 HLA-B 1.13 -1.01 -42.84 -17.36 -3.38 -2.14 -2.49 -12.27 -50.65 1.26
Major histocompatibility complex, class I, B NM_005514 HLA-C 1.13 -1.01 -23.10 -4.54 -9.91 -2.14 -2.49 -4.13 -10.02 1.27





Gene Name Genbank No. Symbol
CYTOKINES & GROWTH FACTORS
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Table 3. Select genes from commercial Human Cancer Inflammation and Immunity 
Crosstalk™ array displaying genes associated with inflammation, growth, signal 
transduction, and antigen presentation. All compounds treated at 10 μM. Treatments 
were compared to 0.1% DMSO as carrier control. T98G cells were treated for 6 h or 24 
h, and triplicate samples pooled before mRNA extraction. Data represented as fold 
change compared to the appropriate time-point control and normalized against house-




E804 7BIO TMF E804 + TMF
7BIO + 





Chemokine ligand 2 NM_002982 CCL2 -6.29 -2.25 -9.35 -23.12 -17.97 -12.28 -1.41 -2.97 -61.80 -14.98
Chemokine ligand 10 NM_004591 CCL20 -4.65 1.92 1.19 -2.19 1.55 4.42 2.77 4.02 1.62 16.23
Cyclooxygenase 2 NM_000963 COX2 -2.06 11.23 5.85 8.53 54.11 13.98 10.06 8.78 5.60 76.77
Interferon gamma NM_000619 IFNG -2.06 -2.75 1.00 1.00 1.00 1.00 -1.15 -4.94 -3.28 -19.60
Interleukin 1α NM_000575 IL1A -8.28 2.13 2.39 -4.56 2.70 -8.20 -1.01 1.32 -3.45 2.41
Interleukin 1β NM_000576 IL1B -3.62 3.16 3.00 -1.35 4.48 -3.82 2.48 2.85 -1.34 9.09
Interleukin 2 NM_000586 IL2 -2.06 -1.40 1.00 -2.57 1.00 1.00 -1.15 -4.07 1.79 1.00
Interleukin 6 NM_000600 IL6 -2.11 -1.27 -1.58 -4.80 2.39 -1.62 1.94 -1.55 -3.80 4.72
Interleukin 12α NM_000882 IL12A -5.38 -2.58 -1.19 -9.13 -1.89 -1.03 1.00 -1.05 -6.65 -1.11
Interleukin 12β NM_002187 IL12B 9.86 -1.16 1.00 60.43 1.00 1.00 -1.15 -1.78 190.64 -2.40
Interleukin 23α subunit p19 NM_016584 IL23A 7.50 8.65 2.78 8.12 4.27 1.38 1.36 2.23 7.59 1.94
Inducible nitric oxide synthase NM_000625 INOS 17.19 1.48 -1.16 26.00 -5.29 21.99 4.21 7.35 99.05 34.46
Toll like receptor 4 NM_138554 TLR4 -6.79 -1.02 1.42 -4.02 -1.11 -2.20 1.92 2.81 -11.15 2.89
Tumor necrosis factor α NM_000594 TNFA -2.06 -2.75 1.00 1.65 1.00 1.00 -1.01 1.00 3.83 1.00
Cytotoxic T-lymphocyte-associated protein 4 NM_005214 CTLA4 -2.06 -2.75 1.00 1.00 1.00 1.00 -1.15 -37.81 -1.16 2.68
Chemokine ligand 5 NM_002994 CXCL5 -1.71 1.16 1.30 1.14 2.65 7.41 5.57 4.68 2.68 5.21
Chemokine ligand 12 NM_000609 CXCL12 -1.13 -1.19 -1.67 -2.08 -2.39 -1.96 -3.05 -1.63 -2.74 -5.80
Indoleamine 2,3-dioxygenase 1 NM_002164 IDO1 -2.06 2.35 1.94 3.77 4.28 4.81 7.05 4.76 -2.26 5.90
Interleukin 4 NM_000589 IL4 2.75 -1.26 1.52 4.91 1.20 1.16 -2.57 1.93 11.46 2.16
Interleukin 8 NM_000584 IL8 -15.24 1.60 -1.04 -8.76 1.90 -1.21 5.55 -1.95 -4.63 3.11
Interleukin 10 NM_000572 IL10 2.71 -1.59 1.53 1.55 1.00 15.45 -1.15 -1.86 3.92 5.88
Interleukin 13 NM_002188 IL13 2.16 1.07 -1.43 3.28 -3.08 15.63 2.01 3.60 11.32 -1.34
Programmed cell death 1 NM_005018 PD1 -2.06 -2.75 1.00 1.00 -15.83 1.00 -1.15 -1.71 1.00 1.00
PD ligand 1 NM_014143 PDL1 1.15 1.58 6.85 1.20 -10.61 -1.17 1.92 3.01 1.64 2.44
Transforming growth factor β1 NM_000660 TGFB1 1.33 1.50 1.14 -1.35 -2.16 1.64 2.02 1.72 1.67 2.08
Epidermal growth factor NM_001963 EGF -1.66 -1.04 -2.02 -3.87 -1.46 -1.56 -1.52 -1.58 -4.20 -2.23
EGF receptor NM_005228 EGFR -4.11 -1.17 -1.41 -2.64 -1.72 -1.42 1.39 1.31 -3.00 2.00
Insulin like growth factor 1 NM_000618 IGF1 -1.37 -2.31 -4.52 1.60 -7.24 -14.96 -549.26 -106.83 -13.50 -98.33
IL-15 NM_000585 IL15 1.42 -1.04 -2.86 -5.20 -1.43 1.13 -1.47 -2.77 -9.13 -2.52
Secreted phosphoprotein 1 NM_000582 SPP1 1.01 -1.43 1.55 1.31 1.71 -1.15 -1.85 1.72 1.05 1.33
Granulocyte macrophage CSF-2 NM_000758 CSF2 -45.27 -3.12 -1.76 -21.77 -12.08 1.42 8.75 1.48 -45.19 2.45
Granulocyte CSF-3 NM_000759 CSF3 6.86 2.11 -1.31 13.15 1.18 3.13 -1.02 1.29 134.99 1.94
Signal transducer and activator of transcription 3 NM_003150 STAT3 -1.22 -1.01 1.44 1.31 1.29 -2.42 1.11 1.46 -1.21 1.47
Toll like receptor 2 NM_003264 TLR2 1.92 -2.48 1.00 1.06 1.00 7.37 1.61 -2.16 6.04 5.19
Toll like receptor 3 NM_003265 TLR3 1.05 1.82 3.08 2.48 3.16 -22.82 1.72 1.03 -8.85 1.91
Major histocompatibility complex, class I, A NM_002116 HLA-B -1.02 1.06 -2.46 -1.47 -1.82 1.00 8.35 1.05 2.16 1.98





T98G gene expression change after 24 hrT98G gene expression change after 6 hr
Gene Name Genbank No. Symbol
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3.3.      Indirubins E804 and 7BIO modulate IL-6 and VEGF-A secretion in 
glioblastoma cell lines 
As a hallmark cytokine marker of a pro-inflammatory environment, IL-6 
secretion by LN-18 and T98G glioma cells was quantified after 6 h and 24 h 
exposure to E804, 7BIO, and in combination with the AHR antagonist TMF. IL-6 
secretion was modestly suppressed, and moderated increased in LN-18 cell by 
E804 and 7BIO, respectively (Figure 4). These effects were completely inhibited 
by TMF. By 24 h post exposure to E804, IL-6 secretion was modestly 
suppressed, and this effect was reversed by co-exposure to TMF. TMF alone 
also increased IL-6 secretion in LN-18 cells. Of note, IL-6 secretion in LN-18 cells 
receiving only the carrier control increased between 6 and 24 h. In contrast to 
LN-18 cells, T98G cells did not secrete more IL-6 between 6 and 24 h 
culture.  As with LN-18 cells, E804 lowered IL-6 secretion during the 6 h 
exposure, while 7BIO increased secretion in T98G cells. Unlike with LN-18 cells, 
addition of TMF increased IL-6 secretion in T98G cells. By 24 h post-exposure, 
7BIO was shown to increase IL-6 secretion, and TMF enhanced this effect.	
Vascular endothelial growth factor-A (VEGF-A) secretion was higher in 
LN-18 cells than in T98G cells at both 6 and 24 h of culture (Figure 5). Indirubin 
E804 suppressed VEGF-A secretion in LN-18 cells at 6 h, but not by 24 h, while 
7BIO increased secretion at 24 h. At 6 h, VEGF-A secretion was inhibited by the 
presence of TMF, and at 24 h the effect continued with cells also receiving E804.  
There was little effect of treatments on VEGF-A secretion in T98G cells at 6 h, 
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with a slight increase from cells treated with E804 and TMF, while 7BIO 
increased secretion alone, and in combination with TMF. The combination of 






Figure 4. The effects of E804 or 7BIO, and/or TMF, on secretion of IL-6 as measured by 
ELISA. All compounds treated at 10 μM. Secretion in a, c) the LN-18 cell line and b, d) 
the T98G cell line, for 6 h (a and b) or 24 h (c and d). Data represent the mean fold 
expression + S.E. of three different experiments. (*) indicates p < 0.05, (**) p < 0.005, 







































































































































Figure 5. The effects of E804 or 7BIO, and/or TMF, on secretion of VEGF-A as 
measured by ELISA. All compounds treated at 10 μM. Secretion in a, c) the LN-18 cell 
line and b, d) the T98G cell line, for 6 h (a and b) or 24 h (c and d). Data represent the 
mean fold expression + S.E. of three different experiments. (*) indicates p < 0.05, (**) p < 




































































































































4.0.  DISCUSSION 
	
	
 In this study I found that, as with many other indirubins, E804 and 7BIO 
are ligands for the AHR, as demonstrated by the induction of cyp1b1 in LN-18 
and T98G glioma cells over the course of 6 to 24 h. Furthermore, this activity can 
be inhibited by AHR antagonism, depending on the time course and cell line.   
Although TMF is used to antagonize the activity of E804 and 7BIO, this flavonoid 
is also a partial agonist at early time points, as demonstrated herein with LN-18 
cells, and by others (Murray et al. 2010). As a partial agonist, it induces cyp1b1 
minimally and continues to block the activity of E804, at least for up to 24 h.  
From observations with LN-18 cells, TMF is not an antagonist against the activity 
of 7BIO. The underlying differences in AHR activity between the two cell lines 
may be due to the observation that basal AHR protein levels are lower in LN-18 
cells than in T98G cells, but the induction of CYPs by typical AHR ligands is 
higher in the former (Gramatzki et al. 2009). 
 The observation of AHR antagonism by TMF in these two glioma lines 
after treatment with E804 may bode well for clinical applications to impede the 
activity of endogenous ligands, namely kynurenines, produced during the 
metabolism of tryptophan by glioma associated TDO2 and IDO1/2. AHR 
activation by kynurenines in gliomas is associated with T-cell suppression and 
immune tolerance in the tumor microenvironment, and polarization of glioma 
associated macrophages towards the M2 phenotype, and thus a tumor-
promoting environment (Guastella et al. 2018, Gabriely and Quintana 2019, 
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Takenaka et al. 2019). Flavonoid compounds like TMF, and many others, are 
common ingredients in plants used as a healthy diet, and pose no toxic threat to 
humans (Hubbard et al. 2017). 
Previous studies have demonstrated anti-inflammatory properties of E804, 
and have shown that this compound targets STAT3 signaling (Chan et al. 2012, 
Miyoshi et al. 2012, Nam et al. 2005, Babcock, Anderson, and Rice 2013).  
Indirubin 7BIO has been shown to induce both caspase-dependent and 
independent cell death in several cancer cell lines, but to my knowledge has not 
been examined for anti-inflammatory or anti-STAT3 signaling activity (Nicolaou et 
al. 2012, Ribas et al. 2006). Herein, I demonstrate that 7BIO induces stat3 gene 
expression in LN-18 and T98G cells, and therefore may not be suitable for 
glioma therapy because of the known pro-tumor role of STAT3 signaling in brain 
cancer. On the other hand, E804 does not induce stat3 gene expression under 
the conditions examined herein. Taken together with aforementioned studies 
indicating its anti-STAT3 signaling properties, this compound may be better 
suited for future anti-glioma studies. 
Gliomas comprise a highly pro-inflammatory neoplasia, secreting large 
amounts of IL-1β, IL-6, and IL-8 in human GBM cell lines and in cultured primary 
tumor cells (Yeung et al. 2013). The driver for these cytokines is typically NF-κB, 
which is expressed at high levels in some gliomas, and may be the cause of 
transitions from the pro-neural subtype to a mesenchymal state (Bhat et al. 
2013). It has been suggested that IL-6 is an autocrine growth factor secreted by 
	 40	
gliomas, and this may be due to continued activation of NF-κB (Shan et al. 2015). 
However, glioma cells also secrete high levels of TGF-β, which contributes to T-
reg activation and immunosuppression seen in the local and systemic 
environment of patients (Gramatzki et al. 2009, Vega, Graner, and Sampson 
2008, Nduom, Weller, and Heimberger 2015). 
 The connection between TGF-β and NF-κB, and roles of IL-6 in glioma-
inflammation cross-talk has been the subject of intense study. It has been 
suggested that TGF-β induces miR-182, and therefore suppresses the gene cyld, 
a deubiquination enzyme and negative regulator of NF-κB signaling components 
(Song et al. 2012). This leads to upregulation and sustained expression of NF- 
κβ. Furthermore, IL-6 secreted by gliomas activates the IL-6/JAK/STAT3 
signaling pathway through an autocrine fashion (Johnson, O'Keefe, and Grandis 
2018). This pathway, in turn, further activates NF-κB signaling, resulting in 
sustained IL-6 secretion (Hendrayani et al. 2016). This may explain the observed 
high background levels of IL-6 secreted by glioma cells in the absence of 
treatment, which were in the range of 3000 – 4000 pg/ml by LN-18 cells, and 
1000 pg/ml by T98G cells. By comparison, LPS-activated macrophages typically 
secrete IL-6 in the range of 300 - 400 pg/ml (Matsebatlela et al. 2015). 
Therefore, identifying small molecules to inhibit this pro-inflammatory 
cross talk in gliomas seems critical going forward. To that end, previous work 
from the Rice lab using the mouse macrophage cell line RAW264.7 
demonstrated that E804 inhibits LPS-stimulated expression of NF-κB, along with 
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expression of il6, il1, nos2, and csf2 (Babcock, Anderson, and Rice 2013). In this 
study I found that E804 slightly reduced IL-6 protein secretion, while other 
treatments, including AHR antagonism, increased production and secretion, and 
especially the combination of 7BIO and TMF at 24 h. It appears that AHR 
antagonism is anti-inflammatory early on following treatments in LN-18 cells, and 
slightly pro-inflammatory in T98G cells at the same time point. These data 
suggest that the potent effect of E804 and TMF on IL-6 protein production and 
secretion is short lived in LN-18 cells. At this point, it is unclear if these 
observations are due to differences in basal levels of AHR between the two cell 
lines.   
 The total anti-inflammatory properties of these treatments in glioma cells 
cannot be determined based solely on IL-6 secretion. To this point, the cancer-
inflammation cross-talk gene array employed in this study yields more 
differences between LN-18 and T98G cells, and the effects of the two indirubins 
and the effects of AHR antagonism. The experimental design allowed us to 
observe the effects of TMF alone on the expression of select genes previously 
determined to have a role in cancer-inflammation cross-talk. From the array, it 
can be deduced that the AHR in LN-18 cells is involved in the expression of ifng, 
ptsg2, il12b, tnfa, il10, il13, the balance between pd1 and pdl1, and even 
expression of mhc1a/b. The mechanisms associated with these changes in gene 
expression is not clear from this study, but LN-18 cells may provide an important 
platform for such future studies. Overall, the role of the AHR in the expression of 
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arrayed genes in T98G cells differed from LN-18 cells. AHR antagonism had the 
opposite effect on expression of ptsg2, il12b, mhc1a/b, and especially igf1, while 
maintaining high expression of pdl1. The downregulation of MHC-1 molecules on 
the surface of glioma cells may benefit natural killer cells because this is a major 
trigger for natural killer activation and target killing.   
 The observations that 7BIO induces expression of stat3, is a potent  
AHR agonist that is not antagonized with TMF, and promotes IL-6 and VEGF-A 
secretion to such a high degree, make it unlikely that 7BIO could be used to 
modulate glioma cells in future studies. On the other hand, E804 has broad anti-
inflammatory properties, is an AHR ligand that can be antagonized in terms of 
AHR activities, and can target not only inflammatory genes, but those associated 
with growth factors and their receptors as well, including anti-VEGF-A secretion.  
Importantly for glioma studies, E804 did not induce stat3 gene expression.  
Moreover, based on other published studies with E804 and other cancer cell 
types, this study supports future research with E804 with clinical applications in 
mind. This study also points to clear differences in responses to treatments 
between glioma cell lines, and suggests that future studies need to take into 
account differences in AHR activities between different glioma lines. 
 The ultimate goal of the research described herein is to replace current 
GBM post-operative practices of implanting carmustine-laden wafers in the cavity 
created by de-bulking the tumor mass. Carmustine is extremely toxic to not only 
glioma cells, but normal tissues as well, with severe negative effects of patients.  
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As an alternative, this study supports the use of E804-ladened wafers along with 
TMF to antagonize the AHR-associated responses of the compound. E804 may 
be anti-inflammatory, thus inhibit autocrine growth factors and cytokines and/or 
their receptors, block STAT3 signaling, and inhibit cyclin-dependent kinases.  
E804 is also an AHR ligand, and therefore it induces the expression of the 
battery of genes associated with AHR activation, including additional AHR 
expression, which is associated with glioma-derived kynurenine production, and 
thus pro-tumor properties. Simultaneous treatment with TMF may alleviate this 
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ABSTRACT 
This study focused on the novel indirubin derivative E804 (indirubin-3’-(2,3 
dihydroxypropyl)-oximether) and investigated its effects on endoplasmic 
reticulum stress in glioblastoma multiforme (GBM) cells in vitro. The unfolded 
protein response (UPR) pathway manages the cellular response to accumulated 
misfolded or unfolded proteins. I employed a gene array of 80+ genes to monitor 
the effect of E804 treatment at 24 h in LN-18 and T98G glioma cell lines, along 
with western blot analysis. The results suggest that E804 affects multiple arms of 
the UPR as indicated by fold changes in genes related to protein binding, protein 
degradation, UPR transcription factors, and apoptosis. Furthermore, these data 
demonstrate a reversal of heightened UPR stress in glioma cells, as shown by 
the down regulation of hsp5, atf6, xbp1, atxn3, and perk. Genes such as hsp5 
and atxn3 have been implicated in tumor cell proliferation, and atf6 and xbp1 
activate a stress response, indicating that E804 may provide a neuroprotective, 
yet anti-proliferative response in tumor cells. Given the sensitive location, brain 
cancer drugs should not induce widespread apoptosis that may affect healthy 
tissue. Desirably, effectors associated with apoptosis such as chop, perk, and 
GADD34 were down regulated by E804. Of note, down-regulation of perk has 
been associated with an improved response to chemotherapy in resistant tumors. 
Taken together, these results indicate that E804 is a strong modulator of the 
UPR in LN-18 and T98G cells and should be pursued further as a potential drug 
for neurological disorders such as GBM.  
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1.0.  INTRODUCTION 
Some of the most difficult diseases to treat and manage are the primary 
brain and central nervous system cancers, of which roughly 30% are gliomas. Of 
these gliomas, glioblastoma multiforme (GBM) (WHO grade IV) is the most 
aggressive and lethal subset (Holland 2000). Found mainly in the cerebral 
hemispheres, GBM may arise from astrocytes, but other cell types may 
contribute as well, including neuronal and oligodendrocyte precursors (Zong, 
Verhaak, and Canoll 2012, Zong, Parada, and Baker 2015, Alcantara Llaguno 
and Parada 2016), which may determine the origin and nature of glioma stem 
cells (Jackson, Hassiotou, and Nowak 2014). Although glioblastoma cannot be 
cured surgically, the first management step is to surgically debulk as much of the 
tumor as possible.  
Following surgery, GBM is usually treated with radiotherapy and 
chemotherapy, or immunotherapy with the goal of slowing tumor growth. Despite 
intense research efforts to date, no current treatments are completely curative 
(Young et al. 2015). Typical chemotherapy options include alkylating agents such 
as lomustine (chloroethyl cyclohexyl nitrosourea - CCNU) and temozolomide 
(TMZ), delivered orally, and carmustine (bischlorethyl nitrosourea -BCNU), 
delivered as an infused wafer directly to the brain post-operatively (Ramirez et al. 
2013, Wei et al. 2014).  Oral medications such as TMZ are difficult to deliver 
across the blood-brain barrier (Ramirez et al. 2013), and implantation of 
carmustine-infused biodegradable polymers has limited success with high risk of 
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brain edema and infection (Omuro and DeAngelis 2013).  Moreover, these 
alkylating agents induce the unfolded protein response (UPR) and apoptosis 
indiscriminately (Hombach-Klonisch et al. 2018), and may be associated with 
severe systemic toxicity as well, including myelosuppression and pulmonary 
toxicity (Hombach-Klonisch et al. 2018).  Thus, pharmacological alternatives to 
alkylating agents are needed. 
 Indirubin is the active ingredient in Danggui Longhui Wan, an ancient 
Chinese herbal remedy for neoplasia and inflammation derived from the plant 
Polygonum tinctorium (Hoessel, Leclerc, Endicott, Nobel, et al. 1999, Leclerc et 
al. 2001). Natural indirubin can be produced by P. tinctorium (Leclerc et al. 
2001), bacteria (Bhushan, Samanta, and Jain 2000) , mollusks, and other 
biological sources (Meijer et al. 2003, Cooksey 2001). Indirubins synthetic 
derivatives are of interest in cancer research because of their ability to inhibit 
cyclin-dependent and glycogen synthase kinases (Leclerc et al. 2001, Cheng et 
al. 2017).  
 In addition to their effects on CDK activity, various indirubin derivatives 
also bind and activate the aryl hydrocarbon receptor (AHR) (Adachi et al. 2001, 
Springs and Rice 2006, Faber et al. 2018, Kawanishi et al. 2003, Scobie, Houke, 
and Rice 2019). The AHR is a member of the basic helix-loop-helix (bHLH-PAS) 
superfamily of proteins and functions as a ligand-activated transcription factor 
(Gu, Hogenesch, and Bradfield 2000) for multiple responsive gene products. 
Most notable of these genes include phase I and II drug-metabolizing enzymes 
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and transporters (Denison et al. 2002, Hu et al. 2007, Nebert et al. 2000, Köhle 
and Bock 2007).  Other gene products include proteins associated with cell cycle 
arrest, such as p21, p57, and p27 (Knockaert et al. 2004). Unlike many 
environmental AHR ligands, such as planar PCBs and TCDD, indirubins are 
metabolized very quickly (Guengerich et al. 2004) by phase I enzymes (CYP1A1, 
CY1B1) induced through AHR activation. It is now clear that the AHR plays a key 
role in a myriad of physiological roles; not only of drug metabolism, but also 
immune regulation, organogenesis, mucosal barrier function, and cell cycle arrest 
(Hubbard, Murray, and Perdew 2015). AHR-indirubin structure activity 
relationships (SARs) vary depending upon specific indirubin derivative structure 
and bioavailability (Blažević et al. 2015).  Further elucidation of biological actions 
of indirubin derivatives is a promising avenue for GBM research. 
One particular indirubin derivative, [indirubin-3’-(2,3 dihydroxypropyl)-
oximether)] (E804) has also been shown to inhibit angiogenesis in human 
umbilical vein endothelial cells (HUVECs) in vivo (Shin and Kim 2012), has 
potent anti-inflammatory properties (Babcock, Anderson, and Rice 2013), inhibits 
STAT3 signaling (Nam et al. 2005a), and has shown promise in other systems as 
well (Kim et al. 2009, Moon et al. 2006, Nicolaou et al. 2012, Shin and Kim 
2012).  Moreover, I recently demonstrated that E804 has potent anti-
inflammatory properties, suppresses STAT3 expression, and is a potent AHR 
ligand in glioma cell lines (Scobie, Houke, and Rice 2019). To my knowledge, it is 
not known if E804 induces apoptosis through the unfolded protein response 
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(UPR), and thus would have undesirable effects in non-tumor cells surrounding 
glioma cells in situ. One recent study demonstrated that select indirubin 
derivatives protect against the UPR in HT22 neuronal cells by down-regulating 
the apoptosis regulator CHOP, although E804 was not one of those examined 
(Kosuge et al. 2017).   
The LN-18 and T98G cell lines were chosen for their sensitivity to indirubin 
compounds such as E804, due to differing basal expression of the aryl 
hydrocarbon receptor (AHR) (Gramatzki et al. 2009). To date, both cell lines 
have been used extensively in both brain cancer and ER stress research 
(Weatherbee, Kraus, and Ross 2016, Nguyen et al. 2019). Therefore, LN-18 and 
T98G cell lines are good models to study the potential neuro-protective effects of 
indirubins via alleviation of ER stress. LN-18 and T98G cells were initially 
collected from grade IV astrocytomas in Caucasian males ages 65 and 61, 
respectively (ATCC).  Others have shown that LN-18 and T98G cells are 
sensitive to UPR pathway induction, especially via PERK signaling (Jia et al. 
2010), and therefore provide a good in vitro system for further exploration. 
Not only do these cell lines have an active protein stress response, they 
also express high levels of tumor suppressor genes that respond to genotoxic 
stress such as p53 and p21. T98G cells typically have higher levels of p53 
protein, as they are homozygous mutant at 237, while LN-18 cells are 
heterozygous mutant at 238. Both cell lines express high levels of p21 and do not 
express p16 (Weller et al. 1998). T98G cells have higher protein levels of BCL-2 
	 51	
apoptotic family proteins, including BCL-2, MCL-1, BCL-X, and BAX. Additionally, 
the LN-18 cell line is generally more sensitive to drug-induced cytotoxicity than 
the T98G line (Weller et al. 1998).  
Herein I show that E804 suppresses the expression of several key genes 
and proteins involved in the UPR, including CHOP, in two glioma cell lines 
differing in AHR activities.  This study supports the use of E804 in future studies 
seeking advancement in the treatment of GBM. 
 
 
2.0.  MATERIALS AND METHODS 
 
2.1. Chemicals: Indirubin-3’-(2,3 dihydroxypropyl)-oximether (E804) was 
obtained from Alexis Biochemical (CA,USA). Stock solution was prepared at 10-2 
M by solubilizing in dimethyl sulfoxide (DMSO, Corning, NY, USA). DMSO carrier 
used at <0.1% v/v. 
 
2.2. Cell culture: Human Glioblastoma Multiforme (GBM) cell lines, LN-18 
(ATCC CRL-2610) and T98G (ATCC CRL-1690), were obtained from ATCC (VA, 
USA) and cultured using Dulbecco’s Modified Eagle’s Medium (DMEM, Cellgro, 
MA, USA) as the base medium. Medium was supplemented with 10% heat-
inactivated fetal bovine serum supplemented with iron (Hyclone, USA), 
20 mM HEPES, 10 mM l-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, 
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110 μg/ml sodium pyruvate, 1% non-essential amino acids (100 × stock), 4.5 g/l 
glucose, and 1.5 g/l of NaHCO3, each from Sigma (Sigma Aldrich, MO, USA). 
Cells were typically grown and maintained at 37 °C with 5% CO2 in Corning 
75 cm2 culture flasks.  
 
2.3. Focused commercial RT-qPCR arrays for Human Unfolded Protein 
Response Plus: LN-18 and T98G cells were seeded at 2 x 106 cells/mL in a 24-
well plate and allowed to adhere for 24 h.  Cells were then treated in triplicate 
with 10 μM E804 or 0.1% DMSO carrier control, in a total of 1 mL complete 
medium per well. Twenty-four hours post-exposure, cells from all three replicates 
were pooled and dissolved in 1 mL of RNAzol (Molecular Research, OH, USA) 
and mRNA was extracted using the RT2 First Strand Kit and according to 
manufacturer’s instructions (Qiagen, Hilden, Germany). Complementary DNA 
was synthesized using RT2 Easy First Strand Kit (Qiagen) and included removal 
of gDNA contamination using elimination mixture supplied by the manufacturer. A 
predesigned Unfolded Protein Response Plus Profile array of 96 genes was 
purchased from Qiagen Corporation (cat # PAHS-089Y) for use with RT² SYBR 
Green ROX qPCR mastermix from the same supplier, and provided instructions 
were followed. Real time-qPCR was performed on a StepOnePlus (Applied 
Biosystems) RT-qPCR machine. For data analysis, the ΔΔCt method was used; 
for each gene, fold-changes were calculated as difference in gene expression 
between untreated controls and treated cell cultures. Data were gathered and 
	 53	
interpreted using software provided by Qiagen. Details on methods have been 
previously published (Matsebatlela et al. 2015, Babcock, Anderson, and Rice 
2013). 
 
2.4. Western Blotting: LN-18 and T98G cells were seeded at 2 x 106 cells/mL in 
T-75 flasks and allowed to adhere for 24 h. Cells were then treated with 10 μM 
E804 or 0.1% DMSO carrier control for 24 h in a total volume of 10 ml.   
Supernatants were then removed, and cells lysed with 1 ml RIPA buffer (50 mM 
Tris HCl, pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% 
SDS) containing Halt™ protease inhibitor cocktail (Thermo Fisher).  Cell lysates 
were incubated on ice for 30 min, then centrifuged at 500 g for 2 min. The 
overlying supernatant was removed and centrifuged again for 20 min at 14,000 g, 
followed by quantification of protein content of overlying supernatants. Twenty-
five µg of lysate protein from each sample were separated by SDS–PAGE on 4-
20% gels (Biorad, Richmond CA USA), and transferred to a PVDF membrane 
(Immobilon-P, EMD Millipore, MA, USA) for 1 h at 100 V on ice. Membranes 
were blocked overnight at 4 °C in 10% bovine calf serum, then probed with 
primary antibody for 1 h, washed, and probed with secondary AP-conjugated 
antibody for 2 h at room temperature. Protein signals were detected using 5-
bromo-4-chloro-3-indolyl-phosphate (BCIP) and Nitro Blue Tetrazolium (NBT) in 
alkaline phosphatase (AP) developer (Fisher). The rabbit polyclonal antibodies 
against ATF6a (ab203119; diluted 1:500) and XBP1 (ab37152; diluted 1:500) 
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were purchased from Abcam, GADD34 (10449-1-AP; diluted 1:333) from Protein 
Tech; and the mouse monoclonal antibody against CHOP (MA1-250; diluted 
1:500) was purchased from Thermo Fisher. Beta-actin loading control antibody 
(AC-15, diluted 1:2500) was purchased from Sigma-Aldrich. Anti-rabbit and anti-
mouse AP-labeled secondary antibodies were diluted 1:2000 (Thermo Fisher). 
The experiment was repeated three times. Band densities were imaged and 
quantified using ImageJ. 
 
 
3.0.  RESULTS  
 
3.1. E804 induces UPR-related gene profiles in LN-18 and T98G glioma cells 
Both LN-18 and T98G cell lines were responsive to the UPR stress-reduction 
properties of E804 (Table 4, Figure 6, Supplemental Table 1).  Genes associated 
with binding of unfolded protein were affected by E804 treatment, especially in 
the T98G cell line. Specifically, hspa1b was up-regulated 96-fold in T98G cells, 
and hspa2 was up-regulated 24- and 81-fold in LN-18 and T98G cells 
respectively. All other genes queried in this class were down-regulated by E804 
in T98G cells, whereas LN-18 cells were primarily unaffected. Genes associated 
with protein degradation, such as herpud1, htra2, mbtps2, and nploc4 were for 
the most part down-regulated by E804, especially in T98G cells. Nploc4 was 
minorly up-regulated in LN-18 cells. The important transcription factor atf6, 
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responsible for signaling one arm of the apoptotic cascade in the UPR, was down 
regulated in both cell lines. Of note, transcription factors atf4, creb3l3, and ire1 
were all minorly up-regulated in both cell lines. Genes involved with apoptosis 
were affected by E804 treatment, including down regulation of Atxn3, chop, and 
perk in both cell lines, and by up to 25-fold in T98G cells. Gadd34 was up-
regulated by 4- and 24-fold in LN-18 and T98G cells, respectively.  
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Table 4. Select genes from commercial Human Unfolded Protein Response Plus™ array displaying genes associated with 
unfolded protein binding, ER associated degradation (ERAD), transcription, and apoptosis. Both cell lines treated with E804 
at 10 μM for 24 h. Treatments were compared to 0.1% DMSO as carrier control.  Samples were run in triplicate and pooled 




Gene	Name	 Entrez	ID	 Symbol	 E804	Treatment	
LN18	 T98G	
		 	 	 	 		
UNFOLDED	PROTEIN	BINDING	 	 		
Chaperonin	containing	TCP1	subunit	4	 10575	 CCT4	 -1.57	 -3.31	
DnaJ	heat	shock	protein	family	(Hsp40)	member	B9	 4189	 DNAJB9	 1.48	 -16.05	
Endoplasmic	reticulum	oxidoreductase	1	beta	 56605	 ERO1B	 1.65	 -5.95	
Heat	shock	protein	family	A	(Hsp70)	member	1B	 3304	 HSPA1B	 -2.41	 96.33	
Heat	shock	protein	family	A	(Hsp70)	member	2	 3306	 HSPA2	 24.00	 81.70	
Heat	shock	protein	family	A	(Hsp70)	member	5	 3309	 HSPA5	 -1.65	 -2.46	
SIL1	nucleotide	exchange	factor	 64374	 SIL1	 -1.41	 -1.58	
T-complex	1	 6950	 TCP1	 1.05	 -1.40	
Torsin	family	1	member	A	 1861	 TOR1A	 -1.26	 -4.23	
		 	 	 	 		
ER	ASSOCIATED	DEGRADATION	(ERAD)	 	 		
Derlin	1	 79139	 DERL1	 -1.46	 3.24	
ER	degradation	enhancing	alpha-mannosidase	like	protein	1	 9695	 EDEM1	 2.33	 1.22	
F-box	protein	6	 26270	 FBXO6	 -1.01	 9.12	
Homocysteine	inducible	ER	protein	with	ubiquitin	like	domain	1	 9709	 HERPUD1	 -1.72	 -12.07	
HtrA	serine	peptidase	2	 27429	 HTRA2	 -4.34	 -9.54	
Membrane	bound	transcription	factor	peptidase,	site	2	 51360	 MBTPS2	 1.25	 -10.75	
NPL4	homolog,	ubiquitin	recognition	factor	 55666	 NPLOC4	 3.11	 -2.29	
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TRANSCRIPTION	FACTORS	 	 		
Activating	transcription	factor	4	 468	 ATF4	 1.97	 1.16	
Activating	transcription	factor	6	 22926	 ATF6	 -1.73	 -2.22	
cAMP	responsive	element	binding	protein	3	like	3	 84699	 CREB3L3	 2.52	 4.17	
Endoplasmic	reticulum	to	nucleus	signaling	1	 2081	 IRE1	 3.34	 2.01	
Endoplasmic	reticulum	to	nucleus	signaling	2	 10595	 IRE2	 1.45	 -1.45	
SREBF	chaperone	 22937	 SCAP	 -1.53	 1.95	
Sterol	regulatory	element	binding	transcription	factor	1	 6720	 SREBF1	 4.44	 -3.68	
X-box	binding	protein	1	 7494	 XBP1	 1.12	 -6.93	
		 	 	 	 		
APOPTOSIS	 	 		
Ataxin	3	 4287	 ATXN3	 -2.20	 -3.85	
CCAAT	enhancer	binding	protein	beta	 1051	 CEBPB	 -4.57	 3.01	
DNA	damage	inducible	transcript	3	 1649	 CHOP	 -8.47	 -25.08	
Protein	phosphatase	1	regulatory	subunit	15A	 23645	 GADD34	 4.10	 24.01	
Eukaryotic	translation	initiation	factor	2	alpha	kinase	3	 9451	 PERK	 -1.79	 -3.20	





Figure 6. KEGG pathway of Protein Processing In Endoplasmic Reticulum, visually 
representing data presented in Table 1. Green boxes indicate fold down-regulation of 
E804-treated sample compared to the control, red boxes indicate fold up-regulation. Fold 
change v- scaled normalized to -1 through 1. Fold change of individual genes are split 





3.2. E804 affects GADD34 protein signaling in T98G glioma cells 
Western blot analysis revealed no difference in protein expression of ATF6, 
sXBP1, uXBP1, or CHOP at 24 h post E804 treatment (Figure 7). GADD34 was 
decreased (p < 0.0001) by E804 in the T98G cell line.  E804 appears to have an 
up-regulatory trend in the LN-18 cell line, as opposed to a down-regulatory trend 
in the T98G cell line. The active spliced XBP1 was expressed at basal levels in 
the LN-18 cell line, but not at all in the T98G cell line, and was unaffected by 
E804 treatment.  
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Figure 7. Protein levels of GADD34, ATF6, XBP1 (spliced and un-spliced), CHOP, and 
loading reference β-Actin, as measured by western blot (A) in both cells lines after 
treatment with E804 for 24 h. Relative protein density from western blot in LN-18 cell line 

























































4.0.  DISCUSSION 
Constitutive UPR activation has been reported in many cancers 
(Doultsinos et al. 2019). Although not completely understood, the IRE1 and 
PERK arms of the UPR appear to play a supporting role in tumorigenesis and 
progression. Due to mutation, hypoxic conditions, glucose deprivation, low pH, 
and rapid growth, glioma cells are exposed to many factors that heighten the risk 
of protein misfolding (Ma and Hendershot 2004). These stressors, combined with 
increased protein requirements, may lead to induction of the UPR. The adaptive 
healing and anti-apoptotic responses of the UPR are first induced in order to 
process the accumulation of misfolded proteins. If unsuccessful, later responses 
may lead to induction of apoptosis. However, tumors appear able to exploit these 
stress response pathways to benefit from initial pathway protective mechanisms, 
while avoiding later-stage apoptosis (Luo and Lee 2013).  Because prolonged, 
chronic activation of the UPR pathways has been implicated in tumor 
progression, targeted down regulation of certain UPR-related genes is a likely 
therapeutic target for GBM and other cancers.  The increase in UPR activity 
during glioma initiation and progression provides a fresh avenue of exploration 
for potential cancer therapeutics. 
In this study I found that E804 induced changes in mRNA abundance in 
both cell lines (LN-18 and T98G), as determined using the commercially 
available qRT-PCR array. Among the groups of genes affected by treatment 
were the heat shock proteins (HSPs). HSPs are involved in an initial protective 
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response within the cell, as they identify and tag misfolded proteins for repair or 
removal (Sajjad, Samson, and Wyttenbach 2010). E804 induced up-regulation of 
hspa2 in both cell lines, and hspa1b in T98G cells. Conversely, hspa5, known as 
the master regulator of the UPR, was down regulated, indicating a dichotomous 
response to E804. Hspa5 has been implicated in an adaptive response to chronic 
stress in cancer. Of note, it has been reported that down-regulation of hspa5 
correlates to slowed glioma growth (Pyrko et al. 2007). Therefore, inhibition of 
hspa5 is currently being investigated as a means to enhance autophagy via the 
UPR (Uckun et al. 2011, Cerezo and Rocchi 2017).  
Another set of genes that may confer protective functions in surrounding 
tissue encodes the transcription factors associated with activating the UPR.  The 
data herein indicates that E804 affects expression levels of atf6, xbp1, and ire1, 
among others. In addition to binding proteins such as hspa5 above that may 
modulate autophagy, transcription factor IRE1 has been linked to autophagy, and 
is up-regulated in both glioma cell lines herein (Høyer-Hansen and Jäättelä 
2007). ATF6 is one of three major transcriptional arms of the UPR and causes 
increased production of stress-response effectors such as XBP1 and pro-
apoptotic factor CHOP (Epple et al. 2013, Yoshida et al. 2001). Down-regulation 
of atf6 was observed in both glioma lines after treatment, which may indicate that 
E804 exeerts a dampening effect on the adaptation to ER stress that occurs in 
malignant tumors such as GBM, while also dampening one arm of the apoptotic 
signal. The down-regulation of both atf6 and xbp1 may indicate neuroprotective 
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effects via dampening of the UPR when these GBM cells are treated with E804 
(Credle et al. 2015). These transcription factors are also known to activate other 
pathways such as STAT3 and thus E804-modulated activation of these genes 
could demonstrate crosstalk processes occurring (Chen and Zhang 2017). 
Considering the physical proximity within which drugs are delivered to 
glioma tumors, it would be undesirable for E804, or similar small molecules, to 
initiate widespread apoptosis. The down-regulation of UPR, atxn3, chop, and 
perk, key regulators of the UPR, indicate that E804 delivers an anti-apoptotic 
signal to these glioma cells. Another important pro-apoptotic gene, gadd34, was 
upregulated in both cell lines, however protein expression of GADD34 was 
suppressed, may indicate that E804 inhibits pro-apoptotic profiles prior to 24 h. 
Until further studies are carried out, the significance of the pro-apoptotic gene 
expression profile over time in response to E804 remains unknown. Of note, 
PERK has been associated with higher-grade gliomas, and the silencing of perk 
has been found to ameliorate chemoresistance (Hou et al. 2015). Thus, the 
modest downregulation of perk by E804 may indicate a potential role as adjuvant 
therapy for E804 in vivo. While CHOP and PERK are pro-apoptotic, ATXN3 is 
responsible for cleaving ubiquitin from proteins marked for degradation. Other 
similar deubiquitylating enzymes have been implicated in cell proliferation during 
oncogenesis (Hussain, Zhang, and Galardy 2009), and thus inhibition of these 
enzymes, such as was seen by E804 herein, have clinical relevance.  
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Indirubin-induced chop down-regulation may be due to inhibition of 
glycogen synthase kinase 3 (GSK-3) (Meares et al. 2011). Additionally, GSK-3 is 
a major regulator of numerous and diverse pathways, and dysregulation of these 
pathways is implicated in many disease types, including cancer (Mancinelli et al. 
2017). GSK-3 regulates the STAT3 pathway, which is also involved in glioma 
development (Ganguly et al. 2018) and has been found to be down-regulated by 
E804 treatment in my prior work (Scobie, Houke, and Rice 2019).  A few studies 
have investigated the UPR in response to other indirubin derivatives (Joshi, 
Kulkarni, and Pal 2013, Meares et al. 2011, Kosuge et al. 2017), however to my 
knowledge this is the first study to examine the glioma UPR in response to E804 
treatment.  E804 is a known activator of the STAT3 cascade, an important 
inflammatory pathway in glioma autocrine signaling during tumorigenesis and 
promotion (McFarland et al. 2013). Of note, STAT3 can be activated in response 
to ER stress, a process partially dependent on the PERK arm of the UPR 
signaling cascade (Meares et al. 2014).   
This study confirms that E804 regulates many genes involved in the 
unfolded protein response, including perk, gadd34, chop, atf6, and xbp1. Such 
regulation of the UPR in GBM cells has implications for treatment of 
neuroinflammatory conditions using this compound, and possibly in combination 
with others. Based on the extreme toxicity of current chemotherapeutic agents 
employed in glioma therapy, alternative and less toxic are needed, while also 
targeting glioma cells and not normal bystander cells of the central nervous 
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system. E804 and other indirubins are likely candidates that should be examined 
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Supplementary Table 1. Select genes from commercial Human Unfolded Protein Response Plus™ array displaying genes 
associated with unfolded protein binding, ER associated degradation (ERAD), transcription, and apoptosis. Both cell lines 
treated with E804 at 10 μM for 24 h. Treatments were compared to 0.1% DMSO as carrier control. Samples were run in 
triplicate and pooled prior to mRNA extraction. Data represented as fold change compared to the control and normalized 
against house-keeping gene expression. 
 
 
	 	 	 	 	
Gene	Name	 Entrez	ID	 Symbol	 E804	Treatment	
LN18	 T98G	
		 	 	 	 		
UNFOLDED	PROTEIN	BINDING	 	 		
calreticulin	 811	 CALR	 -2.10	 1.68	
calnexin	 821	 CANX	 1.40	 -1.03	
chaperonin	containing	TCP1	subunit	4	 10575	 CCT4	 -1.57	 -3.31	
DnaJ	heat	shock	protein	family	(Hsp40)	member	B9	 4189	 DNAJB9	 1.48	 -16.05	
DnaJ	heat	shock	protein	family	(Hsp40)	member	C10	 54431	 DNAJC10	 1.09	 -1.28	
endoplasmic	reticulum	oxidoreductase	1	beta	 56605	 ERO1B	 1.65	 -5.95	
heat	shock	protein	family	A	(Hsp70)	member	1B	 3304	 HSPA1B	 -2.41	 96.33	
heat	shock	protein	family	A	(Hsp70)	member	2	 3306	 HSPA2	 24.00	 81.70	
HtrA	serine	peptidase	2	 27429	 HTRA2	 -4.34	 -9.54	
prefoldin	subunit	5	 5204	 PFDN5	 1.20	 -1.09	
peptidylprolyl	isomerase	A	 5478	 PPIA	 1.05	 -1.50	
SREBF	chaperone	 22937	 SCAP	 -1.53	 1.95	
SEC63	homolog,	protein	translocation	regulator	 11231	 SEC63	 -1.07	 -1.47	
SIL1	nucleotide	exchange	factor	 64374	 SIL1	 -1.41	 -1.58	
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t-complex	1	 6950	 TCP1	 1.05	 -1.40	
torsin	family	1	member	A	 1861	 TOR1A	 -1.26	 -4.23	
UDP-glucose	glycoprotein	glucosyltransferase	1	 56886	 UGGT1	 1.14	 -1.12	
		 	 	 	 		
ER	PROTEIN	FOLDING	QUALITY	CONTROL	 	 		
ER	degradation	enhancing	alpha-mannosidase	like	protein	1	 9695	 EDEM1	 2.33	 1.22	
glucosidase	II	alpha	subunit	 23193	 GANAB	 1.06	 -2.26	
glucosidase	alpha,	neutral	C	 2595	 GANC	 1.27	 -13.20	
protein	kinase	C	substrate	80K-H	 5589	 PRKCSH	 1.12	 1.37	
ribophorin	I	 6184	 RPN1	 1.14	 -1.55	
stress	associated	endoplasmic	reticulum	protein	1	 27230	 SERP1	 -1.43	 -6.06	
endoplasmic	reticulum	protein	44	 23071	 ERP44	 1.13	 -1.87	
UDP-glucose	glycoprotein	glucosyltransferase	1	 56886	 UGGT1	 1.14	 -1.12	
		 	 	 	 		
REGULATION	OF	CHOLESTEROL	METABOLISM	 	 		
insulin	induced	gene	2	 51141	 INSIG2	 1.31	 -3.62	
membrane	bound	transcription	factor	peptidase,	site	1	 8720	 MBTPS1	 1.56	 -1.54	
membrane	bound	transcription	factor	peptidase,	site	2	 51360	 MBTPS2	 1.25	 -10.75	
SREBF	chaperone	 22937	 SCAP	 -1.53	 1.95	
sterol	regulatory	element	binding	transcription	factor	1	 6720	 SREBF1	 4.44	 -3.68	
		 	 	 	 		
REGULATION	OF	TRANSLATION	 	 		
eukaryotic	translation	initiation	factor	2A	 83939	 EIF2A	 1.15	 -1.59	
eukaryotic	translation	initiation	factor	2	alpha	kinase	3	 9451	 PERK	 -1.79	 -3.20	
protein	phosphatase	1	regulatory	subunit	15A	 23645	 GADD34	 4.10	 24.01	
stress	associated	endoplasmic	reticulum	protein	1	 27230	 SERP1	 -1.43	 -6.06	
		 	 	 	 		
ER	ASSOCIATED	DEGRADATION	(ERAD)	 	 		
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autocrine	motility	factor	receptor	 267	 AMFR	 1.72	 1.79	
derlin	1	 79139	 DERL1	 -1.46	 3.24	
ER	degradation	enhancing	alpha-mannosidase	like	protein	1	 9695	 EDEM1	 2.33	 1.22	




HtrA	serine	peptidase	2	 27429	 HTRA2	 -4.34	 -9.54	
HtrA	serine	peptidase	4	 203100	 HTRA4	 2.58	 1.41	
membrane	bound	transcription	factor	peptidase,	site	1	 8720	 MBTPS1	 1.56	 -1.54	
membrane	bound	transcription	factor	peptidase,	site	2	 51360	 MBTPS2	 1.25	 -10.75	
NPL4	homolog,	ubiquitin	recognition	factor	 55666	 NPLOC4	 3.11	 -2.29	
nucleobindin	1	 4924	 NUCB1	 1.38	 -1.18	
OS9	endoplasmic	reticulum	lectin	 10956	 OS9	 -1.24	 1.34	
SEL1L	adaptor	subunit	of	ERAD	E3	ubiquitin	ligase	 6400	 SEL1L	 -1.41	 -1.58	
selenoprotein	S	 55829	 VIMP	 2.10	 1.12	
synoviolin	1	 84447	 SYVN1	 -1.67	 1.41	
SEC62	homolog,	preprotein	translocation	factor	 7095	 SEC62	 1.04	 -1.59	
UBX	domain	protein	4	 23190	 UBXN4	 1.43	 -1.31	
valosin	containing	protein	 7415	 VCP	 -1.76	 -1.79	
		 	 	 	 		
UBIQUITINATION	 	 		




ring	finger	protein	5	 6048	 RNF5	 -1.67	 -3.17	
SEL1L	adaptor	subunit	of	ERAD	E3	ubiquitin	ligase	 6400	 SEL1L	 -1.41	 -1.58	
SEC62	homolog,	preprotein	translocation	factor	 7095	 SEC62	 1.04	 -1.59	
ubiquitin	conjugating	enzyme	E2	G2	 7327	 UBE2G2	 1.51	 -1.43	
UBX	domain	protein	4	 23190	 UBXN4	 1.43	 -1.31	
69	
ubiquitin	recognition	factor	In	ER	associated	degradation	1	 7353	 UFD1L	 -1.11 1.27	
ubiquitin	specific	peptidase	14	 9097	 USP14	 2.01 -1.32
valosin	containing	protein	 7415	 VCP	 -1.76 -1.79
TRANSCRIPTION	FACTORS	
activating	transcription	factor	4	 468	 ATF4	 1.97	 1.16	
activating	transcription	factor	6	 22926	 ATF6	 -1.73 -2.22
ataxin	3	 4287	 ATXN3	 -2.20 -3.85
calreticulin	 811	 CALR	 -2.10 1.68
CCAAT	enhancer	binding	protein	beta	 1051	 CEBPB	 -4.57 3.01
cAMP	responsive	element	binding	protein	3	 10488	 CREB3	 1.71 -1.47
cAMP	responsive	element	binding	protein	3	like	3	 84699	 CREB3L3	 2.52	 4.17	
activating	transcription	factor	6	beta	 1388	 ATF6B	 -1.44 1.39	
DNA	damage	inducible	transcript	3	 1649	 CHOP	 -8.47 -25.08
endoplasmic	reticulum	to	nucleus	signaling	1	 2081	 IRE1	 3.34 2.01
endoplasmic	reticulum	to	nucleus	signaling	2	 10595	 IRE2	 1.45 -1.45
membrane	bound	transcription	factor	peptidase,	site	1	 8720	 MBTPS1	 1.56	 -1.54
prefoldin	subunit	5	 5204	 PFDN5	 1.20	 -1.09
SREBF	chaperone	 22937	 SCAP	 -1.53 1.95
sterol	regulatory	element	binding	transcription	factor	1	 6720	 SREBF1	 4.44	 -3.68
X-box	binding	protein	1 7494	 XBP1	 1.12	 -6.93
PROTEIN	FOLDING	
calreticulin	 811	 CALR	 -2.10 1.68	
calnexin	 821	 CANX	 1.40 -1.03
chaperonin	containing	TCP1	subunit	4	 10575	 CCT4	 -1.57 -3.31
DnaJ	heat	shock	protein	family	(Hsp40)	member	B9	 4189	 DNAJB9	 1.48	 -16.05
DnaJ	heat	shock	protein	family	(Hsp40)	member	C10	 54431	 DNAJC10	 1.09	 -1.28
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endoplasmic	reticulum	oxidoreductase	1	alpha	 30001	 ERO1A	 1.31	 -1.38
heat	shock	protein	family	A	(Hsp70)	member	4	like	 22824	 HSPA4L	 -1.18 -19.76
prefoldin	subunit	5	 5204	 PFDN5	 1.20	 -1.09
peptidylprolyl	isomerase	A	 5478	 PPIA	 1.05	 -1.50
SEC63	homolog,	protein	translocation	regulator	 11231	 SEC63	 -1.07 -1.47
SIL1	nucleotide	exchange	factor	 64374	 SIL1	 -1.41 -1.58
t-complex	1 6950	 TCP1	 1.05 -1.40
torsin	family	1	member	A 1861	 TOR1A	 -1.26 -4.23
endoplasmic	reticulum	protein	44 23071	 ERP44	 1.13 -1.87
UDP-glucose	glycoprotein	glucosyltransferase	1 56886	 UGGT1	 1.14 -1.12
PROTEIN	DISULFIDE	ISOMERIZATION	
DNA	damage	inducible	transcript	3	 1649	 CHOP	 -8.47 -25.08
DnaJ	heat	shock	protein	family	(Hsp40)	member	C10	 54431	 DNAJC10	 1.09	 -1.28
endoplasmic	reticulum	oxidoreductase	1	alpha	 30001	 ERO1A	 1.31	 -1.38
endoplasmic	reticulum	oxidoreductase	1	beta	 56605	 ERO1B	 1.65	 -5.95
protein	disulfide	isomerase	family	A	member	3	 2923	 PDIA3	 1.45	 -1.53
selenoprotein	S	 55829	 VIMP	 2.10	 1.12
sterol	regulatory	element	binding	transcription	factor	1	 6720	 SREBF1	 4.44	 -3.68
endoplasmic	reticulum	protein	44	 23071	 ERP44	 1.13	 -1.87
HEAT	SHOCK	PROTEINS	
DnaJ	heat	shock	protein	family	(Hsp40)	member	B9	 4189	 DNAJB9	 1.48	 -16.05
DnaJ	heat	shock	protein	family	(Hsp40)	member	C10	 54431	 DNAJC10	 1.09	 -1.28
DnaJ	heat	shock	protein	family	(Hsp40)	member	C3	 5611	 DNAJC3	 1.75	 -1.08
heat	shock	protein	family	A	(Hsp70)	member	4	 3308	 HSPA4	 -1.64 -1.36
heat	shock	protein	family	A	(Hsp70)	member	5	 3309	 BIP	 -1.65 -2.46
heat	shock	protein	family	H	(Hsp110)	member	1	 10808	 HSPH1	 1.63 -2.71
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SEC63	homolog,	protein	translocation	regulator	 11231	 SEC63	 -1.07	 -1.47	
		 	 	 	 		
APOPTOSIS	 	 		
mesencephalic	astrocyte	derived	neurotrophic	factor	 7873	 MANF	 -1.70	 -2.00	
ataxin	3	 4287	 ATXN3	 -2.20	 -3.85	
BCL2	associated	X,	apoptosis	regulator	 581	 BAX	 -1.07	 -1.52	
calreticulin	 811	 CALR	 -2.10	 1.68	
CCAAT	enhancer	binding	protein	beta	 1051	 CEBPB	 -4.57	 3.01	
DNA	damage	inducible	transcript	3	 1649	 CHOP	 -8.47	 -25.08	
eukaryotic	translation	initiation	factor	2	alpha	kinase	3	 9451	 PERK	 -1.79	 -3.20	
endoplasmic	reticulum	to	nucleus	signaling	1	 2081	 IRE1	 3.34	 2.01	
endoplasmic	reticulum	to	nucleus	signaling	2	 10595	 IRE2	 1.45	 -1.45	
heat	shock	protein	family	A	(Hsp70)	member	1B	 3304	 HSPA1B	 -2.41	 96.33	
HtrA	serine	peptidase	2	 27429	 HTRA2	 -4.34	 -9.54	
mitogen-activated	protein	kinase	8	 5599	 MAPK8	 -1.05	 -1.99	
mitogen-activated	protein	kinase	9	 5601	 MAPK9	 1.45	 -1.03	
protein	disulfide	isomerase	family	A	member	3	 2923	 PDIA3	 1.45	 -1.53	
protein	phosphatase	1	regulatory	subunit	15A	 23645	 GADD34	 4.10	 24.01	
selenoprotein	S	 55829	 VIMP	 2.10	 1.12	
valosin	containing	protein	 7415	 VCP	 -1.76	 -1.79	
		 	 	 	 		
PATHWAY	ACTIVATION	SIGNATURE	GENES	 	 		
adrenomedullin	2	 79924	 ADM2	 2.49	 1.00	
asparagine	synthetase	(glutamine-hydrolyzing)	 440	 ASNS	 5.23	 2.66	
brain	expressed	X-linked	2	 84707	 BEX2	 1.23	 1.71	
DNA	damage	inducible	transcript	3	 1649	 CHOP	 -8.47	 -25.08	
DnaJ	heat	shock	protein	family	(Hsp40)	member	B9	 4189	 DNAJB9	 1.48	 -16.05	





inhibin	subunit	beta	E	 83729	 INHBE	 1.00	 1.00	
potassium	calcium-
activated	channel	subfamily	M	regulatory	beta	subunit	3	
27094	 KCNMB3	 -1.60	 -4.42	
minichromosome	maintenance	complex	component	4	 4173	 MCM4	 -1.27	 -1.27	
proliferating	cell	nuclear	antigen	 5111	 PCNA	 -4.48	 -1.67	
ribonucleotide	reductase	regulatory	subunit	M2	 6241	 RRM2	 -2.69	 -1.74	
solute	carrier	family	17	member	2	 10246	 SLC17A2	 1.95	 1.00	
tribbles	pseudokinase	3	 57761	 TRIB3	 2.36	 3.76	
thymidylate	synthetase	 7298	 TYMS	 -1.05	 -1.09	
ubiquitin	like	with	PHD	and	ring	finger	domains	1	 29128	 UHRF1	 -2.27	 1.97	
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TRANSCRIPTOMIC RESPONSES IN MACROPHAGES EXPOSED 
TO CONDITIONED MEDIA FROM GBM CELL LINES PRE-
TREATED WITH INDIRUBIN-3’-(2,3 DIHYDROXYPROPYL)-
OXIMETHER AND 6, 2’, 4’-TRIMETHOXYFLAVONE. 
Micaela R. Scobie
Department of Biological Sciences
Clemson University, Clemson SC USA 29634 
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ABSTRACT 
Standard treatments for the highly invasive and malignant brain cancer, 
Glioblastoma Multiforme (GBM), fall short of a cure and come with devastating 
side effects. Small molecules that can program or direct immune surveillance 
towards tumor prevention and/or removal are of intense interest. Glioma-
associated macrophages (GAMs) can comprise 30% of GBM tumor bulk, and are 
known for their tumor promoting abilities and phenotypic plasticity. Studies have 
shown that GAMs can be polarized along a continuum between M1 and M2 
phenotypes, dependent upon the cytokine signaling milieu in the tumor 
microenvironment, thus encouraging a tumor promoting or tumor preventing 
immune response. Previous work has implicated indirubin derivatives, such as 
indirubin-3’-(2,3 dihydroxypropyl)-oximether (E804), as potent modulators of 
inflammatory signaling. As a putative AHR ligand, E804 has been shown to 
regulate cytokines such as IL-1β, STAT3, VEGF, and IL-6 in GBM cells. 
Additionally, AHR antagonist 6, 2’, 4’-trimethoxyflavone (TMF) may enhance 
beneficial immunomodulatory effects of E804 treatment, while inhibiting certain 
effects of AHR pathway activation. Herein, I explore an in vitro model of tumor 
microenvironment signaling via THP-1 monocyte-derived macrophages (MDMs) 
treated with GBM-conditioned media from LN-18 and T98G cells treated with 
E804, E804 + TMF, or control. Transcriptomic sequencing paired with pathway 
analysis revealed E804 and E804+TMF conditioned supernatants significantly 
affected macrophage gene expression in the Cell Cycle and TLR pathways, while 
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only E804 supernatants significantly down-regulated the macrophage Wnt 
pathway. Whether treatment is capable of inducing a shift in macrophage 
polarization remains to be elucidated. Based on this study, both E804 and 
particularly E804 + TMF, should be explored further as a potential therapy for 
instigating an anti-tumor immune response in GBM-resident macrophages.  
Key terms: Glioblastoma Multiforme, GBM, E804, indirubin, TMF, macrophage 
polarization, Wnt, TLR, immunomodulation. 
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1.0.  INTRODUCTION 
With an incidence rate of 3 out of 100,000 in the US and a median life 
expectancy of 15 months (Thakkar et al. 2014), Glioblastoma Multiforme (GBM) 
remains without curative treatment. Classified as a grade IV astrocytoma, GBM is 
a highly invasive and malignant brain tumor (Louis et al. 2016). Standard 
treatment involves first a surgical resection of the tumor, followed by local 
placement of Gliadel wafers infused with DNA-alkylating agents such as 
temozolomide (TMZ) or carmustine. Radiotherapy is often employed concomitant 
with surgery and chemotherapy (Davis 2016). Even with treatment, GBM patient 
prognoses have not improved in over a decade. Continued efforts to understand 
the interplay between the immune system and tumor promotion promises greater 
understanding of drug resistance, along with identification of new treatment 
modalities.  
The heterogeneous composition of gliomas is a key driver in therapeutic 
resistance and stunts therapeutic advancement (Motaln et al. 2015). Inducing a 
targeted anti-cancer immune response, or modifying existing immune processes, 
offers a logical approach to deal with a varied tumor microenvironment. Glioma-
associate macrophages (GAMs) comprise up to 30% of the brain tumor mass 
(Charles et al. 2011), and are brain-intrinsic microglia, or recruited peripheral 
macrophages. Given their dynamic plasticity and programmability, immune cells 
continue to be a logical therapeutic target in treating inflammatory disease such 
as cancer (Matsebatlela et al. 2015). Indeed, GAMs can be co-opted by tumor 
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signaling to assist in tumor growth and metastasis. Dependent on secreted 
cytokines and growth factors in the glioma milieu, GAMs can be polarized 
towards the classically activated M1 phenotype, with tumor fighting 
characteristics, or towards the alternatively activated M2 phenotype, with tumor 
promoting characteristics (Yang and Zhang 2017). Higher M2 presence 
correlates with higher grade glioma, suggesting a tumor enhancing effect (Zhang 
et al. 2016). Because macrophage phenotype is dependent on external signaling 
molecules, encouraging macrophage polarization towards an M1 phenotype is of 
particular interest in cancer treatment. Interestingly, both M1 and M2 
macrophages are capable of phagocytizing tumors given the right stimulus 
(Zhang et al. 2016). Understanding macrophage signaling in response to GBM-
conditioned media is of particular interest. 
Previous studies from the Rice lab have shown indirubin-3’-(2,3 
dihydroxypropyl)-oximether (E804) is an aryl hydrocarbon receptor (AHR) 
agonist, and induces a broad spectrum of immunomodulatory affects in GBM cell 
lines (Scobie, Houke, and Rice 2019). In that study I found E804 to down-
regulate il1a, il1b, il12a, ptgs2, tlr4, and others, and decrease protein secretion of 
IL-6 and VEGF. E804 has also been found to down-regulate STAT3 (Nam et al. 
2005). Interleukin-1b, IL-6, VEGF, and STAT3 are all secreted at high levels by 
in vitro primary and continuous GBM cell lines, and reportedly help drive tumor 
development (Yeung et al. 2013). Targeting the AHR for cancer treatment has 
long been of interest, however it is debated whether AHR activity should be 
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inhibited or amplified (Jin et al. 2019, Reed et al. 2017). Although the complete 
role of the AHR in tumor prevention versus development remains unclear, high 
AHR expression in gliomas is associated with poor prognosis (Takenaka et al. 
2019) and activation may drive gliomagenesis (Gabriely et al. 2017). 6, 2’, 4’-
trimethoxyflavone (TMF) was used herein as a pharmacological inhibitor of the 
AHR, shown previously to effectively inhibit AHR activation when used with E804 
in LN-18 and T98G cell lines (Scobie, Houke, and Rice 2019). Therefore, a 
treatment regimen of TMF as an AHR antagonist plus E804 was explored in 
order to maintain the immunomodulatory benefits of E804 while blocking 
deleterious affects of AHR activation in glioma cells.  
My goal in this study was to model the effects that E804- or E804+TMF-
treated glioblastoma cells have on glioma-associated macrophages using THP-1 
macrophages as an in vitro model. To that aim, I queried gene expression via 
RNA-sequencing in THP-1 macrophages following treatment with conditioned 
media of either the glioma LN-18 or T98G cell lines that had been pre-treated 
with AHR agonist E804, or combination treatment of E804 plus AHR antagonist 
TMF. Here I show that factors secreted by treated glioma cells down-regulate 
important pathways in macrophages such as Wnt and TLR signaling, as well as 
altering expression of genes associated with cholesterol and steroid metabolism. 
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2.0.  MATERIALS AND METHODS 
2.1.  Chemicals:  Indirubin-3’-(2,3 dihydroxypropyl)-oximether (E804) was 
purchased from Alexis Biochemical (CA, USA) and 6, 2′, 4′-trimethoxyflavone 
(TMF) was purchased from Sigma-Aldrich (MO, USA). Stock solutions at 10-2 M 
were prepared by solubilizing compounds in dimethyl sulfoxide (DMSO, Corning, 
NY, USA). Chemical structures for E804 and TMF are shown in Figure 8.  
Figure 8. Chemical structures for a) indirubin-3’-(2,3 dihydroxypropyl)-oximether (E804) 
and b) 6, 2’, 4’-trimethoxyflavone (TMF).  
2.2.  Cell culture:  Human Glioblastoma Multiforme cell lines, LN-18 (CRL-2610) 
and T98G (CRL-1690), and human THP-1 monocytes (TIB-202) were obtained 
from ATCC (VA, USA) and cultured using Dulbecco’s Modified Eagle’s Medium 
(DMEM, Cellgro, MA, USA) as the base medium. Medium was supplemented 
with 10% heat-inactivated fetal calf serum (FCS) with iron (Atlas, CO, USA), 












110 μg/ml sodium pyruvate, 1% non-essential amino acids (100x stock), 4.5 g/l 
glucose, and 1.5 g/l of NaHCO3, each from Sigma-Aldrich. Cells were typically 
grown and maintained at 37 °C with 5% CO2 in Corning 75 cm2 culture flasks.  
2.3.  Treatments:  LN-18 and T98G cell lines were pre-treated with either TMF 
or carrier control for 24 h, before removing old media and replacing with 
appropriate treatment of E804, E804 plus TMF, or carrier control. THP-1 
monocytes were differentiated using 16 nm PMA for 48 h, followed by a 24 h 
resting period in media only. THP-1-differentiated macrophages were then 
treated with 1:2 diluted sterile supernatant from above treated GBM cell lines for 
24 h. All media was removed, cells were washed with cold PBS, dissolved in 1 
mL TRIzol (Invitrogen, MA, USA), and frozen on dry ice prior to mRNA extraction. 
2.4.  Sample preparation and mRNA sequencing:  After a 24 h freezing 
period, mRNA was extracted and purified by poly-a-tail enrichment. Strand-
specific libraries were prepared by kit NEBNext® Ultra™ II Directional RNA 
Library Prep Kit for Illumina® (NEB E7760). Qualified libraries were then 
sequenced on an Illumina HiSeq 4000 Platform using a paired-end 150 run 
(2×150 bases). Sequencing depth approximately 12 GB/sample. 
2.5.  Data analysis:  Data quality control performed using FastQC, and trimmed 
for paired end data with Trimmomatic v-0.36. Reads were aligned to human 
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reference genome GRCh38.p12 using GSNAP (Ensembl release 95 annotation), 
and mapped counts were summarized using Subread featureCounts (frag length 
50 – 600 bp). Raw counts were analyzed with edgeR to estimate the common 
negative binomial dispersion by conditional maximum likelihood (CML). 
Treatment effect was measured by calculating the log2 counts per million (CPM) 
of each gene and then using glm.ft to fit the generalized linear model. Unless 
otherwise noted, differential gene expression was considered statistically 
significant if both the P-value and the false discovery rate (FDR) were <0.05, with 
a log fold change (logFC) > |1|. 
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3.0.  RESULTS 
3.1.  E804- and E804+TMF-treated GBM supernatants affect gene regulation 
in successfully differentiated THP-1 macrophages. 
Untreated THP-1 monocytes versus THP-1 monocytes treated with PMA show 
highly disparate gene profiles based on a heatmap of logCPMs (Fig. 16A). 
Additionally, differentiated THP-1 cells exhibit up-regulation of key genetic 
markers associated with macrophages, showing successful monocyte-to-
macrophage differentiation (Fig. 16B). In order to investigate the polarization 
profiles of THP-1 macrophages treated with glioma culture media of GBM cells 
priorly treated with E804 or E804+TMF, I sequenced the mRNA transcriptome of 
the macrophages in biological triplicate. Macrophages that were cultured with 
E804- or E804+TMF-treated glioma supernatants were compared to 
macrophages that were cultured with carrier-treated glioma supernatants. 
Principle component analysis (PCA) revealed a high variance in gene expression 
between untreated, undifferentiated THP-1 monocytes, and untreated, 
differentiated THP-1 macrophages (Fig. 17). The PCA plot also revealed that 
control-treated LN-18 and control-treated T98G cells induced a common change 
in gene expression in macrophages, while E804- or E804+TMF-treated LN-18 
and T98G cells induced a different set of common changes in in macrophage 
gene expression. 
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Figure 9. A, Heatmap of correlation matrix from log counts per million (logCPM) for 
untreated THP-1 monocytes (n=3) and untreated PMA-differentiated THP-1 
macrophages (n=3). B, Macrophage over monocyte differential gene expression (DGE) 
data of genetic markers associated with macrophages, showing successful monocyte-to-
macrophage differentiation. 
Gene Symbol logFC P	value
Matrix	metalloproteinase	9 mmp9 7.13 <	0.0001
Alpha	2	macroglobulin a2m 6.63 <	0.0001
Apolipoprotein-E apoe 5.92 <	0.0001
Macrophage	scavenger	receptor msr1 4.93 <	0.0001
FC	gamma	receptor	III fcgr3a 4.87 <	0.0001
Integrin	alpha	M	(CD11b) itgam 2.79 <	0.0001
Integrin	beta	2	(CD18) itgb2 2.50 <	0.0001
Toll-like	receptor	4 tlr4 2.00 <	0.0001
Chitinase	3	Like	1 chi3l1 1.38 <	0.0001
Transcription	Factor	EC tfec 1.33 <	0.0001
A	 B	
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Figure 10. Two-dimensional Principle Component Analysis (PCA) plot of transcriptome 
of macrophages cultured with unconditioned media (grey diamonds), macrophages 
cultured with control-treated LN-18 supernatants (orange circles), macrophages cultured 
with E804-treated LN-18 supernatants (light blue squares), macrophages cultured with 
E804 plust TMF-treated LN-18 supernatants (bright green triangles), macrophages 
cultured with control-treated T98G supernatants (red circles), macrophages cultured with 
E804-treated T98G supernatants (navy blue squares), macrophages cultured with E804 
plus TMF-treated T98G supernatants (dark green triangles), and undifferentiated 
monocytes cultured with unconditioned media, showing variance in gene expression 
across all samples. All treatments n=3. 
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3.2.  E804- and E804+TMF-treated GBM supernatants exert more effect on 
macrophage gene regulation than does GBM cell line type. 
A heatmap of logCPM values from the 500 most variable genes (unsupervised 
hierarchical clustering, scaled by row) revealed drastic clustering of treatment 
groups away from gene clustering of control groups (Fig. 18). Furthermore, 
clustering revealed the effect of supernatant treatment was more dependent on 
E804 or E804+TMF treatment groups over that of GBM cell lines. Thus, the 
addition of TMF influences macrophage gene expression to a greater extent than 
GBM cell line. 
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Figure 11. Heatmap of the top 500 most highly variable genes in macrophages after 
treatment, based on log counts per million (logCPM). Scaling by row revealed clustering 
of macrophages cultured with GBM cells (LN-18, light blue; T98G, green) treated with 
control media (purple), versus macrophages cultured with GBM cells treated with either 
E804 (orange) or E804+TMF (red) .  
control	 E804	 E804+TMF	




3.3.  Macrophages experience strong up- and down-regulation of genes 
following treatment with conditioned medium.  
To delineate extreme gene expression differences in macrophages cultured with 
GBM-treated supernatants versus macrophages cultured with GBM controls, I 
selected genes with a |log2 fold change (logFC)|  > 4 and p-value < 0.001 (Fig. 
12). Treated macrophages (all treatments over respective controls) experienced 
down-regulation of genes involved in hydrolase activity, cytokine activity, and 
protein binding (FUCA1, IL1A, CYP1A1). Separately, only macrophages treated 
with E804-GBM supernatants (Fig. 12A, 12C) experienced up-regulation of a 
gene involved in promoting IFN-producing dendritic cells (SPIB), and down-
regulation of genes involved in growth factor activity and enzyme inhibition 
(ANGPTL4, LEFTY1, RNA45SN2). Macrophages treated with E804+TMF-GBM 
supernatants (Fig. 12B, 12D) experienced up-regulation of genes involved in 
chemokine signaling and binding (CCR7, CXCL10, CXCL13, IFI44L, KLHL38) 
and down-regulation of genes involved in enzyme and microtubule activity 
(ADAMTS12, DNAH10, NPTX1, SEMA6B, SV2B). 
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Figure 12. Volcano plots of transcriptional differences in macrophages between 
culturing with E804- or E804+TMF-treated GBM supernatants, versus culturing with 
control-treated GBM supernatants. Individual differences are plotted as log2 fold change 
vs. –log10P value. All points are P < 0.01, and all points P < 0.0001 are colored orange. 




3.4.  Macrophages show mixed M1/M2 polarization following treatment with 
conditioned medium. 
In order to determine whether or not supernatant treatment was polarizing the 
macrophages towards an M1 or M2 genotype, I focused exclusively on genes 
that have been reported in the literature as M1 or M2 gene markers (Fig. 13). M1 
genes queried included CCL2, CCR7, CD80, CXCL19, CXCL11, GPR18, IL1B, 
IL6 KCCN2, and MARCO. M2 genes queried included CXCL12, CCR2, EGR2, 
IL10, MRC1, and MYC. Expression profiles of M1 and M2 associated genes were 
mixed up- and down-regulated, in all treatment groups. 
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Figure 13. Log fold change (LogFC) for genes implicated in M1 or M2 macrophage 
polarization. a) Macrophages cultured with E804-treated LN-18 supernatants, b) 
macrophages cultured with E804-treated T98G supernatants, c) macrophages cultured 
with E804 plus TMF-treated LN-18 supernatants, d) macrophages cultured with E804 
























































































































































































3.5. Significantly up- and down-regulated genes analyzed separately for GO 
term enrichment, show differences in treatment effect on macrophage gene 
regulation.  
In order to determine biological pathway function, the top GO terms for biological 
processes were generated using R package enrichGO including genes with p-
value <0.01 and |logFC| > 1 (Fig. 14). GO term lists were generated for up-
regulated and down-regulated genes separately. GO terms presented are those 
that were found represented in both LN-18-E804 and T98G-E804 treatments, or 
both LN-18-E804+TMF and T98G-E804+TMF treatments. All enriched GO terms 
for up-regulated genes are presented, and up to the top 5 GO terms for down-
regulated genes are presented. Up-regulated terms (Fig. 14A, 14B) common 
among all treatment groups included Organic hydroxy compound metabolic 
process, Hormone metabolic process, and Leukocyte migration. The up-
regulated term unique to GBM-E804+TMF treatment was Positive regulation of 
vasculature development. Down-regulated terms (Fig. 14C, 14D) common 
among all treatment groups included Leukocyte differentiation, Regulation of 
leukocyte activation, Positive regulation of cytokine production, T cell activation 
and Positive regulation of cell adhesion. Down-regulated terms unique to GBM-
E804 treatment were Skeletal system development and Regulation of protein 
binding; while terms unique to GBM-E804+TMF treatment included Leukocyte 
migration, Regulation of multi-organism process, Negative regulation of cytokine 
production, Adaptive immune response based on somatic recombination of 
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immune receptors built from immunoglobulin superfamily domains, and 
Homeostasis of number of cells.  
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Figure 14. GO terms involved in biological processes that are significantly enriched (P < 
0.01). Venn diagrams show overlap in GO terms enriched in a) up-regulated and c) 
down-regulated gene lists between macrophages cultured with E804-treated GBM 
supernatants and macrophages cultured with E804 plus TMF-treated GBM 
supernatants. Same GO terms as displayed in Venn diagrams, b) for up-regulated and 
d) down-regulated gene lists, with number of genes involved in each GO term plotted on
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3.6.  Barcode enrichment plots of key GO terms show distribution of gene 
regulation within gene set. 
Barcode plots display gene set enrichment for key GO terms (Fig. 15 – 20). 
Terms affected by both E804 and E804+TMF supernatant treatments include 
hormone metabolic process (up-regulated, Fig. 15), leukocyte differentiation 
(down-regulated, Fig. 16), and T cell activation (down-regulated, Fig. 17). Terms 
affected by E804 supernatant treatment include skeletal system development 
(down-regulated, Fig. 18). Terms affected by E804+TMF supernatant treatment 
include positive regulation of vasculature development (up-regulated, Fig. 19), 
leukocyte migration (down), and homeostasis of number of cells (down-
regulated, Fig. 20). Genes that were significantly differentially expressed, and 
present in a GO term, are listed (Tables 5 – 10).  
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Figure 15. Barcode plots for GO:0042445 term “hormone metabolic process” show over-
representation in treatments versus controls. Enrichment distribution between up- and 
down-regulated genes for macrophages cultured with a) E804-treated LN18 
supernatant, b) E804 plus TMF-treated LN18 supernatant, c) E804-treated T98G 
supernatant, and d) E804 plus TMF-treated T98G supernatant. P < 0.01, n=3.  




Table 5. Gene lists from over represented GO term Hormone Metabolic Process 
(GO:0042445), as displayed in barcode plot in fig. 15, for macrophages cultured with 
E804-treated LN18 supernatant, E804-treated T98G supernatant, E804 plus TMF-











Symbol Log FC P-value Symbol Log FC P-value Symbol Log FC P-value Symbol Log FC P-value
EGR1 -5.03 <	0.0001 DHRS9 -3.15 <	0.0001 DHRS9 -3.30 <	0.0001 EGR1 -3.32 <	0.0001
DHRS9 -3.39 <	0.0001 CYP26B1 -2.94 <	0.0001 HSD11B1 -3.07 <	0.0001 HSD11B1 -2.85 <	0.0001
HSD11B1 -2.82 <	0.0001 HSD11B1 -2.61 <	0.0001 ALDH1A3 -2.50 <	0.0001 DHRS9 -2.68 <	0.0001
ALDH1A3 -2.61 <	0.0001 ALDH1A3 -2.45 <	0.0001 PLB1 -1.55 <	0.0001 ALDH1A3 -2.23 <	0.0001
PLB1 -1.94 <	0.0001 EGR1 -2.27 <	0.0001 ECE1 -1.55 <	0.0001 PDGFRA -1.69 <	0.0001
PDGFRA -1.89 <	0.0001 PDGFRA -2.19 <	0.0001 PDGFRA -1.46 <	0.0001 ECE1 -1.63 <	0.0001
ECE1 -1.76 <	0.0001 PLB1 -1.79 <	0.0001 GAL -1.37 <	0.0001 PLB1 -1.34 <	0.0001
CYP26B1 -1.70 <	0.0001 RPE65 -1.41 <	0.0001 STAR -1.22 <	0.0001 SPP1 -1.22 <	0.0001
RPE65 -1.58 <	0.0001 ECE1 -1.38 <	0.0001 ALDH8A1 1.05 <	0.0001 TCF7L2 -1.06 <	0.0001
STAR -1.43 <	0.0001 TCF7L2 -1.04 <	0.0001 RBP1 1.14 <	0.0001 PCSK6 -1.00 <	0.0001
CYP46A1 -1.34 <	0.0001 ALDH1A2 1.16 <	0.0001 STC2 1.15 <	0.0001 PPARGC1A 1.02 <	0.0001
TCF7L2 -1.22 <	0.0001 POR 1.24 <	0.0001 ALDH1A2 1.20 <	0.0001 RBP4 1.13 <	0.0001
GAL -1.20 <	0.0001 CYP19A1 1.36 <	0.0001 RDH12 1.22 <	0.0001 DIO2 1.20 <	0.0001
STC2 1.00 <	0.0001 ALDH8A1 1.36 <	0.0001 HSD17B14 1.23 <	0.0001 RDH5 1.21 <	0.0001
ADM 1.03 <	0.0001 HSD17B14 1.44 <	0.0001 DGKQ 1.34 <	0.0001 CYP19A1 1.40 <	0.0001
DDO 1.06 <	0.0001 RDH5 1.75 <	0.0001 RBP4 1.40 <	0.0001 POR 1.41 <	0.0001
DGKQ 1.15 <	0.0001 STC2 1.82 <	0.0001 HSD11B2 1.53 <	0.0001 TG 1.45 <	0.0001
HSD17B7 1.24 <	0.0001 IL1B 1.86 <	0.0001 POR 1.59 <	0.0001 HSD17B14 1.57 <	0.0001
IL1B 1.38 <	0.0001 TG 1.97 <	0.0001 IL1B 1.70 <	0.0001 CRABP2 1.72 <	0.0001
HSD17B14 1.48 <	0.0001 PAX8 2.07 <	0.0001 RDH5 1.72 <	0.0001 STC2 1.80 <	0.0001
RDH12 1.50 <	0.0001 DIO2 2.10 <	0.0001 SRD5A2 1.73 <	0.0001 SRD5A2 1.95 <	0.0001
POR 1.55 <	0.0001 SRD5A2 2.22 <	0.0001 PAX8 2.07 <	0.0001 IL1B 2.15 <	0.0001
RDH5 1.60 <	0.0001 TIPARP 2.52 <	0.0001 TG 2.11 <	0.0001 AKR1C2 2.18 <	0.0001
ALDH8A1 1.60 <	0.0001 CRABP2 2.59 <	0.0001 AKR1C2 2.11 <	0.0001 PAX8 2.25 <	0.0001
ALDH1A2 1.85 <	0.0001 AKR1C2 2.69 <	0.0001 CRABP2 2.13 <	0.0001 TIPARP 2.96 <	0.0001
PAX8 2.16 <	0.0001 CYP11A1 3.21 <	0.0001 DIO2 2.52 <	0.0001 CYP1B1 4.00 <	0.0001
AKR1C2 2.20 <	0.0001 CYP1B1 3.55 <	0.0001 TIPARP 2.85 <	0.0001 CYP1A1 10.21 <	0.0001
TIPARP 2.51 <	0.0001 CYP1A1 8.91 <	0.0001 CYP1B1 4.02 <	0.0001
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Figure 16. Barcode plots for GO:0002521 term “leukocyte differentiation” show under-
representation in treatments versus controls. Enrichment distribution between up- and 
down-regulated genes for macrophages cultured with a) E804-treated LN18 
supernatant, b) E804 plus TMF-treated LN18 supernatant, c) E804-treated T98G 
supernatant, and d) E804 plus TMF-treated T98G supernatant. P < 0.01, n=3.  




Table	6.	Gene lists from under represented GO term Leukocyte Differentiation 
(GO:0002521), as displayed in barcode plot in fig. 16, for macrophages cultured with 
E804-treated LN18 supernatant, E804-treated T98G supernatant, E804 plus TMF-
treated LN18 supernatant, and E804 plus TMF-treated T98G supernatant (n=3). 
Symbol Log FC P-value Symbol Log FC P-value Symbol Log FC P-value Symbol Log FC P-value
EGR3 -5.20 <	0.0001 SOCS1 -4.58 <	0.0001 CCR7 -4.30 <	0.0001 EGR3 -5.25 <	0.0001
EGR1 -5.03 <	0.0001 CCR7 -4.16 <	0.0001 PLA2G2D -3.27 <	0.0001 CCR7 -4.55 <	0.0001
SOCS1 -3.79 <	0.0001 PLA2G2D -3.05 <	0.0001 VCAM1 -3.05 <	0.0001 EGR1 -3.32 <	0.0001
CCR7 -3.56 <	0.0001 CLEC4E -2.94 <	0.0001 CLEC4E -2.84 <	0.0001 CLEC4E -3.18 <	0.0001
PLA2G2D -3.41 <	0.0001 CYP26B1 -2.94 <	0.0001 TNFRSF18 -2.79 <	0.0001 TNFRSF18 -2.61 <	0.0001
ZBTB16 -3.37 <	0.0001 EGR3 -2.81 <	0.0001 DCSTAMP -2.46 <	0.0001 VCAM1 -2.51 <	0.0001
VCAM1 -3.22 <	0.0001 DLL4 -2.78 <	0.0001 ZBTB16 -2.44 0.0002 FOS -2.50 <	0.0001
DLL4 -2.99 <	0.0001 DCSTAMP -2.60 <	0.0001 DLL4 -2.41 <	0.0001 POU4F2 -2.26 <	0.0001
MIR223 -2.80 <	0.0001 VNN1 -2.50 <	0.0001 POU4F2 -2.35 <	0.0001 VNN1 -2.25 <	0.0001
CLEC4E -2.74 <	0.0001 VCAM1 -2.47 <	0.0001 SOCS1 -2.34 <	0.0001 KLF6 -2.23 <	0.0001
CLEC4D -2.55 <	0.0001 EGR1 -2.27 <	0.0001 AXL -2.28 <	0.0001 DLL4 -2.21 <	0.0001
AXL -2.53 <	0.0001 CR2 -2.26 <	0.0001 VNN1 -2.08 <	0.0001 PLA2G2D -2.08 <	0.0001
VNN1 -2.52 <	0.0001 POU4F2 -2.22 <	0.0001 MIR223 -1.93 <	0.0001 AXL -2.03 <	0.0001
POU4F2 -2.50 <	0.0001 KLF6 -2.07 <	0.0001 CLEC4D -1.88 0.0001 POU2F2 -1.99 <	0.0001
DCSTAMP -2.37 <	0.0001 AXL -2.02 <	0.0001 BCL2 -1.87 <	0.0001 SOCS1 -1.98 <	0.0001
BCL2 -2.30 <	0.0001 ZBTB16 -2.01 0.0030 CD83 -1.78 <	0.0001 BCL2 -1.98 <	0.0001
CBFA2T3 -2.16 <	0.0001 PIK3R6 -1.88 <	0.0001 CCL19 -1.72 <	0.0001 DCSTAMP -1.93 <	0.0001
CD83 -2.05 <	0.0001 BCL2 -1.87 <	0.0001 BCL6 -1.69 <	0.0001 IRF7 -1.89 <	0.0001
MIR17HG -1.94 <	0.0001 CCL19 -1.72 <	0.0001 MT1G -1.66 <	0.0001 GPR18 -1.77 <	0.0001
MYC -1.90 <	0.0001 CBFA2T3 -1.72 <	0.0001 POU2F2 -1.65 <	0.0001 TRIB1 -1.76 <	0.0001
FZD7 -1.83 <	0.0001 SLC46A2 -1.71 <	0.0001 IRF7 -1.60 <	0.0001 IKZF3 -1.72 <	0.0001
IL18R1 -1.72 <	0.0001 LILRB1 -1.66 <	0.0001 RSAD2 -1.60 <	0.0001 BCL6 -1.69 <	0.0001
FOS -1.72 <	0.0001 IL18R1 -1.64 <	0.0001 GPR18 -1.55 <	0.0001 CCL19 -1.69 <	0.0001
TLR2 -1.72 <	0.0001 FZD7 -1.63 <	0.0001 MYC -1.53 <	0.0001 CD83 -1.62 <	0.0001
CR2 -1.71 <	0.0001 BCL6 -1.63 <	0.0001 IKZF3 -1.51 <	0.0001 LILRB1 -1.60 <	0.0001
CCL19 -1.70 <	0.0001 TLR2 -1.61 <	0.0001 TLR2 -1.50 <	0.0001 MIR223 -1.54 <	0.0001
CYP26B1 -1.70 <	0.0001 POU2F2 -1.60 <	0.0001 LEF1 -1.48 <	0.0001 CD80 -1.53 <	0.0001
RSAD2 -1.66 <	0.0001 IRF7 -1.59 <	0.0001 AICDA -1.48 0.0001 RSAD2 -1.53 <	0.0001
POU2F2 -1.62 <	0.0001 TNFRSF18 -1.59 <	0.0001 FZD7 -1.41 <	0.0001 PIK3R6 -1.52 <	0.0001
MT1G -1.61 <	0.0001 GPR18 -1.54 <	0.0001 CD80 -1.39 <	0.0001 TLR2 -1.49 <	0.0001
IKZF3 -1.59 <	0.0001 MIR223 -1.54 <	0.0001 PIK3R6 -1.37 <	0.0001 GAS6 -1.44 <	0.0001
BCL6 -1.57 <	0.0001 CLEC4D -1.50 <	0.0001 CDK6 -1.33 <	0.0001 MEF2C -1.43 <	0.0001
IL31RA -1.57 <	0.0001 CD83 -1.47 <	0.0001 NRARP -1.33 <	0.0001 FZD7 -1.43 <	0.0001
IRF7 -1.53 <	0.0001 FOS -1.45 <	0.0001 KLF6 -1.33 <	0.0001 IL18R1 -1.41 <	0.0001
NRARP -1.49 <	0.0001 RSAD2 -1.45 <	0.0001 MEF2C -1.32 <	0.0001 CDK6 -1.36 <	0.0001
CCR2 -1.48 <	0.0001 CD80 -1.45 <	0.0001 FOXP1 -1.31 <	0.0001 LILRB2 -1.35 <	0.0001
CD1D -1.48 <	0.0001 MEF2C -1.39 <	0.0001 MIR17HG -1.30 <	0.0001 CR2 -1.34 0.0006
TNFRSF18 -1.44 <	0.0001 IL18 -1.36 <	0.0001 IL18 -1.25 <	0.0001 MYC -1.34 <	0.0001
CDK6 -1.43 <	0.0001 SFRP1 -1.33 <	0.0001 CR2 -1.24 0.0029 SLC46A2 -1.34 0.0010
GPR18 -1.43 <	0.0001 MYC -1.31 <	0.0001 CCR2 -1.20 <	0.0001 LEF1 -1.33 <	0.0001
CD80 -1.35 <	0.0001 CDK6 -1.27 <	0.0001 IL18R1 -1.19 <	0.0001 ZBTB16 -1.33 0.0258
SFRP1 -1.34 <	0.0001 LEF1 -1.26 <	0.0001 HMGB1 -1.17 <	0.0001 NRROS -1.33 <	0.0001
IL18 -1.30 <	0.0001 CCR2 -1.25 <	0.0001 ADA -1.15 <	0.0001 IL18 -1.33 <	0.0001
LEF1 -1.28 <	0.0001 TESC -1.25 <	0.0001 NRROS -1.11 <	0.0001 DLL1 -1.29 <	0.0001
PPARGC1B -1.27 <	0.0001 MIR17HG -1.25 <	0.0001 TYRO3 -1.10 <	0.0001 CBFA2T3 -1.29 <	0.0001
MEF2C -1.27 <	0.0001 NRARP -1.22 <	0.0001 CBFA2T3 -1.06 <	0.0001 NRARP -1.24 <	0.0001
FOXP1 -1.22 <	0.0001 RASGRP1 -1.15 <	0.0001 PRTN3 -1.03 <	0.0001 ADA -1.22 <	0.0001
RASGRP1 -1.22 <	0.0001 CD1D -1.14 <	0.0001 HDAC9 -1.01 <	0.0001 FOXP1 -1.17 <	0.0001
KLF6 -1.22 <	0.0001 ADA -1.13 <	0.0001 IL6 1.04 0.0030 TYRO3 -1.16 <	0.0001
NRROS -1.14 <	0.0001 TNFSF4 -1.06 <	0.0001 FZD9 1.14 <	0.0001 MIR17HG -1.14 <	0.0001
SLC9B2 -1.09 <	0.0001 FOXP1 -1.05 <	0.0001 FAM20C 1.16 <	0.0001 TESC -1.10 <	0.0001
BATF3 -1.09 <	0.0001 IKZF3 -1.05 <	0.0001 TCF7 1.19 <	0.0001 PLCL2 -1.06 <	0.0001
PIK3R6 -1.09 <	0.0001 IL31RA -1.05 <	0.0001 VEGFA 1.20 <	0.0001 CLEC4D -1.04 0.0152
MYB -1.05 <	0.0001 NRROS -1.04 <	0.0001 RUNX2 1.20 <	0.0001 PPARGC1B -1.02 <	0.0001
ADA -1.03 <	0.0001 PPARGC1B -1.04 <	0.0001 GPR183 1.23 <	0.0001 FAM20C 1.01 <	0.0001
EOMES -1.03 <	0.0001 TNFRSF11A -1.04 <	0.0001 PRR7 1.37 <	0.0001 CEBPE 1.03 <	0.0001
MSH2 -1.01 <	0.0001 SATB1 -1.03 <	0.0001 BMP4 1.39 <	0.0001 RHOH 1.05 <	0.0001
TUSC2 1.01 <	0.0001 VEGFA 1.02 <	0.0001 TLR9 1.43 <	0.0001 TLR9 1.06 0.0003
GPR183 1.03 <	0.0001 GLO1 1.02 <	0.0001 SH3PXD2A 1.49 <	0.0001 GPR183 1.08 <	0.0001
RARA 1.09 <	0.0001 VSIR 1.04 <	0.0001 CEACAM1 1.73 0.0019 PIR 1.09 <	0.0001
RUNX2 1.11 <	0.0001 TCF7 1.08 <	0.0001 ROR2 2.42 <	0.0001 VEGFA 1.17 <	0.0001
TCF7 1.14 <	0.0001 BMP4 1.16 <	0.0001 IL10 3.68 <	0.0001 GLO1 1.20 <	0.0001
LIG4 1.15 <	0.0001 PIR 1.18 <	0.0001 KIT 3.87 <	0.0001 RUNX2 1.25 <	0.0001
VSIR 1.15 <	0.0001 TLR9 1.28 <	0.0001 SH3PXD2A 1.30 <	0.0001
BAD 1.21 <	0.0001 PRR7 1.33 <	0.0001 GPR55 1.44 <	0.0001
KIT 1.28 <	0.0001 ROR2 1.64 <	0.0001 CEACAM1 1.49 0.0035
CEBPE 1.28 <	0.0001 IL6 1.77 <	0.0001 BMP4 1.76 <	0.0001
CEACAM1 1.44 <	0.0001 KIT 1.87 <	0.0001 ROR2 2.28 <	0.0001
ROR2 1.78 <	0.0001 IL10 2.82 <	0.0001 IL10 2.64 <	0.0001
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Figure 17. Barcode plots for GO:0042110 term “T-cell activation” show under-
representation in treatments versus controls. Enrichment distribution between up- and 
down-regulated genes for macrophages cultured with a) E804-treated LN18 
supernatant, b) E804 plus TMF-treated LN18 supernatant, c) E804-treated T98G 
supernatant, and d) E804 plus TMF-treated T98G supernatant. P < 0.01, n=3.  




Table 7. Gene lists from under represented GO term T Cell Activation (GO:0042110), as 
displayed in barcode plot in fig. 17, for macrophages cultured with E804-treated LN18 
supernatant, E804-treated T98G supernatant, E804 plus TMF-treated LN18 supernatant, 
and E804 plus TMF-treated T98G supernatant (n=3). 
Symbol Log FC P-value Symbol Log FC P-value Symbol Log FC P-value Symbol Log FC P-value
EGR3 -5.20 <	0.0001 SOCS1 -4.58 <	0.0001 CCR7 -4.30 <	0.0001 EGR3 -5.25 <	0.0001
EGR1 -5.03 <	0.0001 CCR7 -4.16 <	0.0001 HHLA2 -3.74 <	0.0001 CCR7 -4.55 <	0.0001
SOCS1 -3.79 <	0.0001 HHLA2 -4.07 <	0.0001 CAV1 -3.71 <	0.0001 RIPOR2 -3.46 <	0.0001
CCR7 -3.56 <	0.0001 RIPOR2 -3.78 <	0.0001 PLA2G2D -3.27 <	0.0001 CAV1 -3.35 <	0.0001
RIPOR2 -3.51 <	0.0001 CD24 -3.30 <	0.0001 VCAM1 -3.05 <	0.0001 EGR1 -3.32 <	0.0001
CAV1 -3.43 <	0.0001 PLA2G2D -3.05 <	0.0001 RIPOR2 -3.03 <	0.0001 GJA1 -3.22 <	0.0001
PLA2G2D -3.41 <	0.0001 CLEC4E -2.94 <	0.0001 CLEC4E -2.84 <	0.0001 HHLA2 -3.20 <	0.0001
ZBTB16 -3.37 <	0.0001 CYP26B1 -2.94 <	0.0001 TNFRSF18 -2.79 <	0.0001 CLEC4E -3.18 <	0.0001
VCAM1 -3.22 <	0.0001 CAV1 -2.93 <	0.0001 CD24 -2.69 <	0.0001 P2RX7 -2.85 <	0.0001
DLL4 -2.99 <	0.0001 EGR3 -2.81 <	0.0001 P2RX7 -2.59 <	0.0001 CD24 -2.85 <	0.0001
CD24 -2.84 <	0.0001 DLL4 -2.78 <	0.0001 TNFRSF4 -2.47 <	0.0001 TNFRSF4 -2.66 <	0.0001
HHLA2 -2.84 <	0.0001 P2RX7 -2.74 <	0.0001 ZBTB16 -2.44 0.0002 TNFRSF18 -2.61 <	0.0001
CLEC4E -2.74 <	0.0001 VNN1 -2.50 <	0.0001 GJA1 -2.43 <	0.0001 VCAM1 -2.51 <	0.0001
TNFRSF4 -2.61 <	0.0001 VCAM1 -2.47 <	0.0001 DLL4 -2.41 <	0.0001 VNN1 -2.25 <	0.0001
P2RX7 -2.56 <	0.0001 GJA1 -2.31 <	0.0001 SOCS1 -2.34 <	0.0001 DLL4 -2.21 <	0.0001
CLEC4D -2.55 <	0.0001 EGR1 -2.27 <	0.0001 VNN1 -2.08 <	0.0001 PLA2G2D -2.08 <	0.0001
VNN1 -2.52 <	0.0001 ZBTB16 -2.01 0.0030 CLEC4D -1.88 0.0001 SOCS1 -1.98 <	0.0001
BCL2 -2.30 <	0.0001 PIK3R6 -1.88 <	0.0001 BCL2 -1.87 <	0.0001 BCL2 -1.98 <	0.0001
CD83 -2.05 <	0.0001 PRLR -1.87 <	0.0001 CD83 -1.78 <	0.0001 GPR18 -1.77 <	0.0001
FGL2 -2.03 <	0.0001 BCL2 -1.87 <	0.0001 FGL2 -1.78 <	0.0001 BCL6 -1.69 <	0.0001
GJA1 -1.95 <	0.0001 FGL2 -1.75 <	0.0001 CCL19 -1.72 <	0.0001 CCL19 -1.69 <	0.0001
PRLR -1.84 <	0.0001 CCL19 -1.72 <	0.0001 PRLR -1.69 <	0.0001 PRLR -1.65 <	0.0001
FZD7 -1.83 <	0.0001 SLC46A2 -1.71 0.0001 BCL6 -1.69 <	0.0001 CD44 -1.64 <	0.0001
IDO1 -1.80 <	0.0001 TNFRSF4 -1.67 <	0.0001 CD44 -1.67 <	0.0001 CD83 -1.62 <	0.0001
IL18R1 -1.72 <	0.0001 LILRB1 -1.66 <	0.0001 RSAD2 -1.60 <	0.0001 LILRB1 -1.60 <	0.0001
CCL19 -1.70 <	0.0001 IL18R1 -1.64 <	0.0001 GPR18 -1.55 <	0.0001 VSIG4 -1.57 <	0.0001
CYP26B1 -1.70 <	0.0001 FZD7 -1.63 <	0.0001 CD274 -1.53 <	0.0001 CD80 -1.53 <	0.0001
RSAD2 -1.66 <	0.0001 BCL6 -1.63 <	0.0001 VSIG4 -1.53 <	0.0001 RSAD2 -1.53 <	0.0001
BCL6 -1.57 <	0.0001 TNFRSF18 -1.59 <	0.0001 LEF1 -1.48 <	0.0001 PIK3R6 -1.52 <	0.0001
CD44 -1.56 <	0.0001 GPR18 -1.54 <	0.0001 IDO1 -1.46 <	0.0001 FGL2 -1.51 <	0.0001
PRKCQ -1.54 <	0.0001 PDE5A -1.54 <	0.0001 FZD7 -1.41 <	0.0001 LAX1 -1.49 0.0049
PIK3CG -1.53 <	0.0001 CD44 -1.52 <	0.0001 CD80 -1.39 <	0.0001 FZD7 -1.43 <	0.0001
NRARP -1.49 <	0.0001 CLEC4D -1.50 0.0010 PIK3R6 -1.37 <	0.0001 IL18R1 -1.41 <	0.0001
CCR2 -1.48 <	0.0001 CD83 -1.47 <	0.0001 CDK6 -1.33 <	0.0001 CD274 -1.41 <	0.0001
CD1D -1.48 <	0.0001 RSAD2 -1.45 <	0.0001 NRARP -1.33 <	0.0001 CDK6 -1.36 <	0.0001
TNFRSF18 -1.44 <	0.0001 CD80 -1.45 <	0.0001 FOXP1 -1.31 <	0.0001 LILRB2 -1.35 0.0001
CDK6 -1.43 <	0.0001 PIK3CG -1.44 <	0.0001 FYN -1.30 <	0.0001 IDO1 -1.35 <	0.0001
GPR18 -1.43 <	0.0001 IDO1 -1.42 <	0.0001 IL18 -1.25 <	0.0001 SLC46A2 -1.34 0.0010
CD80 -1.35 <	0.0001 VSIG4 -1.40 <	0.0001 PIK3CG -1.24 <	0.0001 LEF1 -1.33 <	0.0001
CD274 -1.31 <	0.0001 IL18 -1.36 <	0.0001 CCR2 -1.20 <	0.0001 ZBTB16 -1.33 0.0258
IL18 -1.30 <	0.0001 FYN -1.33 <	0.0001 IL18R1 -1.19 <	0.0001 IL18 -1.33 <	0.0001
LEF1 -1.28 <	0.0001 CDK6 -1.27 <	0.0001 HMGB1 -1.17 <	0.0001 CDH26 -1.33 <	0.0001
VSIG4 -1.25 <	0.0001 LEF1 -1.26 <	0.0001 ADA -1.15 <	0.0001 FYN -1.25 <	0.0001
FOXP1 -1.22 <	0.0001 CCR2 -1.25 <	0.0001 SRC 1.02 <	0.0001 PDCD1LG2 -1.25 <	0.0001
RASGRP1 -1.22 <	0.0001 NRARP -1.22 <	0.0001 CCDC88B 1.03 <	0.0001 NRARP -1.24 <	0.0001
FYN -1.19 <	0.0001 RASGRP1 -1.15 <	0.0001 IL6 1.04 0.0030 ADA -1.22 <	0.0001
PIK3R6 -1.09 <	0.0001 CD1D -1.14 <	0.0001 CD300A 1.05 <	0.0001 FOXP1 -1.17 <	0.0001
CDH26 -1.08 0.0002 ADA -1.13 <	0.0001 TCF7 1.19 <	0.0001 SLC11A1 -1.13 <	0.0001
MYB -1.05 <	0.0001 BTN3A1 -1.09 <	0.0001 RUNX2 1.20 <	0.0001 CLEC4D -1.04 0.0152
BTN3A1 -1.04 <	0.0001 PDCD1LG2 -1.08 <	0.0001 GPR183 1.23 <	0.0001 NCK2 -1.02 <	0.0001
ADA -1.03 <	0.0001 TNFSF4 -1.06 <	0.0001 SPTA1 1.32 <	0.0001 PIK3CG -1.01 <	0.0001
EOMES -1.03 <	0.0001 FOXP1 -1.05 <	0.0001 PRR7 1.37 <	0.0001 BTN3A1 -1.00 <	0.0001
NCK2 -1.02 <	0.0001 SATB1 -1.03 <	0.0001 BMP4 1.39 <	0.0001 PDE5A -1.00 0.0002
CD300A 1.03 <	0.0001 SLC11A1 -1.01 <	0.0001 TNFSF14 1.65 <	0.0001 SRC 1.00 <	0.0001
MAPK8IP1 1.03 0.0001 PRNP 1.02 <	0.0001 CCL2 1.69 <	0.0001 RHOH 1.05 <	0.0001
GPR183 1.03 <	0.0001 VSIR 1.04 <	0.0001 IL1B 1.70 <	0.0001 GPR183 1.08 <	0.0001
RARA 1.09 <	0.0001 TCF7 1.08 <	0.0001 CEACAM1 1.73 0.0019 CCL2 1.16 <	0.0001
RUNX2 1.11 <	0.0001 BMP4 1.16 <	0.0001 FGL1 1.96 <	0.0001 RUNX2 1.25 <	0.0001
TNFRSF13C 1.11 0.0028 FKBP1B 1.16 <	0.0001 EFNB2 2.15 <	0.0001 SPTA1 1.25 <	0.0001
TCF7 1.14 <	0.0001 SRC 1.24 <	0.0001 JAML 2.26 <	0.0001 CEACAM1 1.49 0.0035
LIG4 1.15 <	0.0001 TNFRSF13C 1.31 0.0005 IGF1 3.24 <	0.0001 FGL1 1.65 <	0.0001
VSIR 1.15 <	0.0001 PRR7 1.33 <	0.0001 CD7 3.49 <	0.0001 TNFSF14 1.67 <	0.0001
TNFSF14 1.16 <	0.0001 TNFSF14 1.35 <	0.0001 IL10 3.68 <	0.0001 JAML 1.73 <	0.0001
JAML 1.17 <	0.0001 CCL2 1.37 <	0.0001 KIT 3.87 <	0.0001 BMP4 1.76 <	0.0001
BAD 1.21 <	0.0001 FGL1 1.53 <	0.0001 IL1B 2.15 <	0.0001
SPTA1 1.21 <	0.0001 SLA2 1.64 0.0002 CD7 2.23 <	0.0001
PRNP 1.23 <	0.0001 CD7 1.66 <	0.0001 EFNB2 2.24 <	0.0001
SRC 1.27 <	0.0001 EFNB2 1.75 <	0.0001 IL10 2.64 <	0.0001
KIT 1.28 <	0.0001 IL6 1.77 <	0.0001 IGF1 2.95 <	0.0001
MAP3K8 1.29 <	0.0001 IL1B 1.86 <	0.0001 KIT 3.78 <	0.0001
EFNB2 1.32 <	0.0001 KIT 1.87 <	0.0001
NLRC3 1.33 0.0008 IGF1 2.76 <	0.0001
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Figure 18. Barcode plots for GO:0001501 term “skeletal system development” show 
under-representation in treatments versus controls. Enrichment distribution between up- 
and down-regulated genes for macrophages cultured with a) E804-treated LN18 
supernatant, and b) E804-treated T98G supernatant. P < 0.01, n=3.  




Table 8. Gene lists from under represented GO term Skeletal System Development 
(GO:0001501), as displayed in barcode plot in fig. 18, for macrophages cultured with 
E804-treated LN18 supernatant, E804-treated T98G supernatant, E804 plus TMF-
treated LN18 supernatant, and E804 plus TMF-treated T98G supernatant (n=3). 
Symbol Log FC P-value Symbol Log FC P-value
WNT7B -4.07 <	0.0001 TP63 -3.45 <	0.0001
ZBTB16 -3.37 <	0.0001 CYP26B1 -2.94 <	0.0001
TP63 -3.24 <	0.0001 P2RX7 -2.74 <	0.0001
P2RX7 -2.56 <	0.0001 WNT7B -2.70 <	0.0001
TNFRSF11B -2.12 <	0.0001 GJA1 -2.31 <	0.0001
UNCX -2.07 <	0.0001 PDGFRA -2.19 <	0.0001
BMP8B -1.98 <	0.0001 ARID5B -2.04 <	0.0001
GJA1 -1.95 <	0.0001 ZBTB16 -2.01 0.0030
PDGFRA -1.89 <	0.0001 BBX -1.75 <	0.0001
WDR48 -1.87 <	0.0001 BMP8B -1.69 <	0.0001
PBX1 -1.86 <	0.0001 ALX4 -1.67 <	0.0001
DMRT2 -1.79 <	0.0001 LILRB1 -1.66 <	0.0001
GHRL -1.72 <	0.0001 WDR48 -1.54 <	0.0001
CYP26B1 -1.70 <	0.0001 EYA1 -1.52 0.0017
ACVR2A -1.64 <	0.0001 CD44 -1.52 <	0.0001
ARID5B -1.58 <	0.0001 GHRL -1.51 <	0.0001
CD44 -1.56 <	0.0001 SCIN -1.51 <	0.0001
TEAD4 -1.54 <	0.0001 PITX2 -1.50 0.0004
CSGALNACT1 -1.53 <	0.0001 TNFRSF11B -1.43 <	0.0001
TBX3 -1.53 <	0.0001 ACVR2A -1.42 <	0.0001
TWIST1 -1.48 <	0.0001 MEF2C -1.39 <	0.0001
MEF2D -1.46 <	0.0001 GDF11 -1.38 <	0.0001
FGF2 -1.45 <	0.0001 FGFR3 -1.33 0.0009
PAX5 -1.45 <	0.0001 SFRP1 -1.33 <	0.0001
DLX1 -1.45 <	0.0001 FGF2 -1.32 <	0.0001
GDF11 -1.42 <	0.0001 EXT1 -1.32 <	0.0001
BBX -1.41 <	0.0001 MEF2D -1.31 <	0.0001
EXT1 -1.37 <	0.0001 TWIST1 -1.28 <	0.0001
SIX1 -1.36 <	0.0001 CSGALNACT1 -1.22 <	0.0001
SFRP1 -1.34 <	0.0001 TBX3 -1.19 <	0.0001
SCIN -1.33 <	0.0001 HOXA5 -1.18 <	0.0001
ALX4 -1.32 <	0.0001 COL19A1 -1.17 <	0.0001
TRIM45 -1.30 <	0.0001 PITX1 -1.17 <	0.0001
MBTD1 -1.27 <	0.0001 RYR1 -1.16 <	0.0001
FOXN3 -1.27 <	0.0001 UNCX -1.14 0.0013
PPARGC1B -1.27 <	0.0001 DMRT2 -1.13 <	0.0001
MEF2C -1.27 <	0.0001 FOXN3 -1.11 <	0.0001
EYA1 -1.25 0.0060 ZNF385A -1.10 <	0.0001
AMER1 -1.25 <	0.0001 CHSY1 -1.07 <	0.0001
TGFB2 -1.23 <	0.0001 FOXP1 -1.05 <	0.0001
ZNF385A -1.23 <	0.0001 PPARGC1B -1.04 <	0.0001
FOXP1 -1.22 <	0.0001 SIX1 -1.02 <	0.0001
TYMS -1.19 <	0.0001 TGFB3 -1.00 0.0012
PITX2 -1.16 0.0081 CTSK 1.07 <	0.0001
FGFR3 -1.10 0.0060 FMN1 1.14 <	0.0001
SLC9B2 -1.09 <	0.0001 COL1A1 1.15 0.0048
PITX1 -1.07 0.0002 BMP4 1.16 <	0.0001
NAB2 -1.06 <	0.0001 NPR2 1.18 0.0002
CHSY1 -1.05 <	0.0001 RARG 1.22 <	0.0001
RYR1 -1.05 0.0002 SNORC 1.24 <	0.0001
NSD2 -1.03 <	0.0001 POR 1.24 <	0.0001
USP1 -1.02 <	0.0001 PAPPA2 1.38 <	0.0001
MAF 1.00 <	0.0001 INSIG1 1.45 <	0.0001
SLC39A1 1.03 <	0.0001 SNAI2 1.49 <	0.0001
CTSK 1.04 <	0.0001 CDKN1C 1.58 0.0088
RARA 1.09 <	0.0001 ROR2 1.64 <	0.0001
RUNX2 1.11 <	0.0001 KIT 1.87 <	0.0001
HOXB7 1.12 0.0005 CMKLR1 2.05 <	0.0001
SNAI2 1.17 0.0006 TIPARP 2.52 <	0.0001
TGFBI 1.22 <	0.0001 IGF1 2.76 <	0.0001

















Figure 19. Barcode plots for GO:1904018 term “positive regulation of vasculature 
development” show over-representation in treatments versus controls. Enrichment 
distribution between up- and down-regulated genes for macrophages cultured with a) 
E804 plus TMF-treated LN18 supernatant, and b) E804 plus TMF-treated T98G 
supernatant. P < 0.01, n=3.  





Table 9. Gene lists from over represented GO term Positive Regulation of Vasculature 
Development (GO:1904018), as displayed in barcode plot in fig. 19, for macrophages 
cultured with E804-treated LN18 supernatant, E804-treated T98G supernatant, E804 
plus TMF-treated LN18 supernatant, and E804 plus TMF-treated T98G supernatant 
(n=3). 
Positive	Regulation	of	Vasculature	Development	(GO:1904018)
Symbol Log FC P-value Symbol Log FC P-value
TERT -3.30 <	0.0001 EGR1 -3.32 <	0.0001
ADAM12 -2.70 <	0.0001 ADAM12 -2.62 <	0.0001
CX3CR1 -2.16 <	0.0001 CX3CR1 -2.54 <	0.0001
GHRL -1.62 <	0.0001 TERT -2.31 <	0.0001
HGF -1.47 <	0.0001 HGF -1.60 <	0.0001
PIK3R6 -1.37 <	0.0001 PIK3R6 -1.52 <	0.0001
DDAH1 -1.30 <	0.0001 TWIST1 -1.51 <	0.0001
TWIST1 -1.29 <	0.0001 CELA1 -1.46 <	0.0001
PLK2 -1.24 <	0.0001 DDAH1 -1.40 <	0.0001
BTG1 -1.20 <	0.0001 GHRL -1.40 <	0.0001
C5AR1 -1.17 <	0.0001 C5AR1 -1.35 <	0.0001
JUP -1.15 <	0.0001 TBXA2R -1.31 <	0.0001
FGF2 -1.14 <	0.0001 DLL1 -1.29 <	0.0001
ANXA3 -1.13 <	0.0001 ANXA3 -1.26 <	0.0001
RAPGEF2 -1.05 <	0.0001 JUP -1.25 <	0.0001
CELA1 -1.03 0.0068 BTG1 -1.25 <	0.0001
HDAC9 -1.01 <	0.0001 PLK2 -1.15 <	0.0001
LRG1 1.02 <	0.0001 RAPGEF3 -1.04 0.0108
HK2 1.16 <	0.0001 VEGFA 1.17 <	0.0001
VEGFA 1.20 <	0.0001 CXCL8 1.19 <	0.0001
PTGS2 1.22 <	0.0001 FLT1 1.21 <	0.0001
PIK3C2A 1.24 <	0.0001 LRG1 1.22 <	0.0001
PDGFD 1.27 <	0.0001 CCR3 1.22 0.0003
IL1B 1.70 <	0.0001 HK2 1.31 <	0.0001
CEACAM1 1.73 0.0019 BMPER 1.41 <	0.0001
F3 1.89 <	0.0001 CEACAM1 1.49 0.0035
EFNB2 2.15 <	0.0001 PDGFD 1.53 <	0.0001
GATA6 2.19 <	0.0001 GATA6 1.62 <	0.0001
CCL24 2.52 <	0.0001 F3 2.10 <	0.0001
ANGPTL4 3.43 <	0.0001 IL1B 2.15 <	0.0001
THBS1 3.55 <	0.0001 EFNB2 2.24 <	0.0001
IL10 3.68 <	0.0001 IL10 2.64 <	0.0001
KIT 3.87 <	0.0001 CCL24 2.69 <	0.0001
CYP1B1 4.02 <	0.0001 THBS1 2.90 <	0.0001
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Figure 20. Barcode plots for GO:0048872 term “homeostasis of number of cells” show 
under-representation in treatments versus controls. Enrichment distribution between up- 
and down-regulated genes for macrophages cultured with a) E804 plus TMF-treated 
LN18 supernatant, and b) E804 plus TMF-treated T98G supernatant. P < 0.01, n=3.  





Table 10. Gene lists from under represented GO term Homeostasis of Number of Cells 
(GO:0048872), as displayed in barcode plot in fig. 20, for macrophages cultured with 
E804-treated LN18 supernatant, E804-treated T98G supernatant, E804 plus TMF-
treated LN18 supernatant, and E804 plus TMF-treated T98G supernatant (n=3). 
Symbol Log FC P-value Symbol Log FC P-value
CCR7 -4.30 < 0.0001 KLF2 -4.95 < 0.0001
ADGRF5 -3.18 < 0.0001 CCR7 -4.55 < 0.0001
P2RX7 -2.59 < 0.0001 P2RX7 -2.85 < 0.0001
AXL -2.28 < 0.0001 ADGRF5 -2.67 < 0.0001
RHEX -1.96 < 0.0001 AXL -2.03 < 0.0001
CDH2 -1.88 < 0.0001 BCL2 -1.98 < 0.0001
BCL2 -1.87 < 0.0001 RHEX -1.97 < 0.0001
ACVR2A -1.72 < 0.0001 CDH2 -1.74 < 0.0001
TGFBR3 -1.69 < 0.0001 BCL6 -1.69 < 0.0001
ISG15 -1.69 < 0.0001 ACVR2A -1.57 < 0.0001
BCL6 -1.69 < 0.0001 SH2B2 -1.50 < 0.0001
HMGB2 -1.61 < 0.0001 SMO -1.49 < 0.0001
WDR48 -1.43 < 0.0001 MEF2C -1.43 < 0.0001
SH2B2 -1.37 < 0.0001 CDK6 -1.36 < 0.0001
CDK6 -1.33 < 0.0001 ISG15 -1.35 < 0.0001
MEF2C -1.32 < 0.0001 ADA -1.22 < 0.0001
MIR17HG -1.30 < 0.0001 HMGB2 -1.19 < 0.0001
SMO -1.17 < 0.0001 WDR48 -1.17 < 0.0001
ADA -1.15 < 0.0001 MIR17HG -1.14 < 0.0001
ILDR2 -1.07 < 0.0001 ILDR2 -1.13 < 0.0001
EZH2 -1.07 < 0.0001 TGFBR3 -1.10 < 0.0001
KLF2 -1.07 0.0004 EZH2 -1.05 < 0.0001
VEGFA 1.20 < 0.0001 GPR183 1.08 < 0.0001
GPR183 1.23 < 0.0001 VEGFA 1.17 < 0.0001
SPTA1 1.32 < 0.0001 SPTA1 1.25 < 0.0001
BMP4 1.39 < 0.0001 TNFSF14 1.67 < 0.0001
TNFSF14 1.65 < 0.0001 BMP4 1.76 < 0.0001
DYRK3 1.68 < 0.0001 DYRK3 2.08 < 0.0001
KIT 3.87 < 0.0001 KIT 3.78 < 0.0001
Homeostasis	of	Number	of	Cells	(GO:0048872)
 LN18 E804+TMF sup  T98G E804+TMF sup
Macrophages	cultured	with Macrophages	cultured	with
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3.7.  KEGG analysis reveals significant down-regulation of TLR, Cell Cycle, 
and Wnt pathways. 
KEGG pathway analysis revealed that DEGs were significantly enriched across 
all treatments in the toll-like receptor (TLR) signaling pathway (Fig. 21), as well 
as the cell cycle pathway (Fig. 22). Cell cycle pathway enrichment was more 
down-regulated by LN-18-E804 or LN-18-E804+TMF supernatants, as compared 
to T98G supernatants. Conversely, the Wnt pathway was only down-regulated by 
E804 supernatant treatment (Fig. 23). Additionally, two key ligands for the Wnt 
pathway, Wnt7b and Wnt10a, were also down-regulated by all treatments (Fig. 
24). Further analysis of DEGs that were silenced by E804+TMF supernatant 
treatment, but down-regulated by E804 supernatant treatment, revealed that 7 of 
these genes are involved in the Wnt pathway (Fig. 25, Table 11). When TMF was 
introduced, for the E804+TMF supernatant treatment, the Wnt pathway was no 
longer significantly down-regulated.  
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Figure 21. KEGG view of the Toll-Like Receptor (TLR) Signaling Pathway, showing 
multiple-sample data. DGE of macrophages cultured with a) E804-treated or b) 
E804+TMF-treated LN-18 (left side of box) or T98G supernatants (right side of box), 
compared to controls. Green represents down-regulated z-score, red represents up-















Figure 23. KEGG view of the Wnt Signaling Pathway, showing multiple-sample data. 
DGE of macrophages cultured with E804-treated LN-18 (left side of box) or T98G 
supernatants (right side of box), compared to controls. Green represents down-regulated 
z-score, red represents up-regulated z-score.
E804	 LN18|T98G	
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Figure 24. Log fold change (LogFC) for Wnt pathway ligands a) Wnt7b and b) Wnt10a in 
macrophages following culture with supernatants from E804-treated LN-18 or T98G 













































































Figure 25. Heatmap of DGE in cultured macrophages inhibited by addition of TMF to 
treated GBM-supernatants. Blue represents down-regulated genes, red represents up-
regulated genes, and yellow represents zero DGE. No scaling. 
E804	 E804+TMF	
LN18 T98G	 LN18 T98G	
Genes	inhibited	by	addition	of	TMF	
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Table 11. Differential gene expression (DGE) of macrophages cultured with E804 or 
E804+TMF-treated GBM supernatants. Genes shown are involved in the Wnt pathway, 
and are down-regulated by E804-treated supernatants, but not differential expressed 










Bicaudal-C	1 BICC1 80114 -1.08 -1.11 0.00 0.00
Epidermal	growth	factor	receptor EGFR 1956 -1.48 -1.20 0.00 0.00
Frizzled	class	receptor	4 FZD4 8322 -1.25 -1.11 0.00 0.00
Glypican	5 GPC5 2262 -1.31 -1.52 0.00 0.00
NKD	inhibitor	of	WNT	signaling	pathway	2 NKD2 85409 -1.09 -1.27 0.00 0.00
Protocadherin	11	Y-Linked PCDH11Y 83259 -1.17 -1.26 0.00 0.00
Secreted	frizzled	related	protein	1	 SFRP1 6422 -1.34 -1.33 0.00 0.00
Gene	expression	of	supernatant-treated	Macrophages
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4.0.  DISCUSSION 
My study demonstrates that supernatants from glioma cells (conditioned 
media) treated with E804 alone, or E804 plus TMF, modulate the expression of 
genes in macrophages associated with several key pathways. From mRNA 
sequencing in conjunction with GO term and pathway analysis, I observed 
modulation of key terms involved with macrophage-GBM function, such as down-
regulation of the Cell Cycle, Toll Like Receptor (TLR), and Wnt pathways, and 
modulation of genes involved in steroid hormone metabolism and vasculature 
development. Other studies have reported the importance of GBM-secreted 
factors on macrophage function and polarization, such as extracellular vesicles 
(van der Vos et al. 2015), periostin (Zhou et al. 2015), and macrophage migration 
inhibitory factor (Otvos et al. 2016).  
I did not observe a conclusive polarization towards M1 or M2 macrophage 
based on literature-backed gene expression profiles. Neither GBM cell type nor 
AHR antagonism conclusively changed the ratio of M1 to M2 genes. However, 
both E804 and E804+TMF supernatants induced down-regulation of genes 
involved in GO terms Leukocyte Differentiation and T Cell Activation, along with 
the Cell Cycle KEGG pathway. Thus, the GBM treated supernatants were able to 
dampen a lymphocyte activation response in THP-1 macrophages compared to 
controls. E804 has already been shown to inhibit CDKs in the cell cycle (Leclerc 
et al. 2001, Hoessel, Leclerc, Endicott, Noble, et al. 1999) and suppress 
inflammatory profiles in GBM cells (Scobie, Houke, and Rice 2019), therefore 
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supernatant induced inhibition of key genes involved in the cell cycle such as 
TGF-β may be due to altered states of differentiation in those macrophages. 
Moreover, the disparate reaction of macrophages to supernatants from the 
different GBM cell lines may be in part due to differences in AHR activity in the 
two cell lines (Gramatzki et al. 2009), and validates the need for personalized 
testing in cancer therapy.  
Additionally, the Toll-Like Receptor (TLR) pathway was down-regulated by 
E804 and E804+TMF supernatants. While nfkb was unaffected, many upstream 
pathway components were down-regulated such as tlr2, tlr3, tlr7/8, akt, and jnk, 
as well as downstream effectors such as mip1a, cd80, ip10, and itac. The down-
regulation of these genes could have a significant effect on subsequent immune 
cell recruitment and activation. Of note, E804-conditioned supernatant up-
regulated pro-inflammatory genes il1b and il8, both of which are linked to pro-
tumor activity, but also linked to M1 polarization (Chittezhath et al. 2014). 
Addition of AHR antagonist inhibited up-regulation of il8, supporting concomitant 
use of E804 plus TMF.  TLR2 signaling has been implicated in STAT3-driven 
gastric tumorigenesis (Tye et al. 2012), as well as macrophage-assisted immune 
evasion in GBM via down-regulation of MHC II proteins (Qian et al. 2018).
Additionally, M2 bone marrow derived macrophage polarization by hepatoma-
conditioned media was driven by TLR2 (Chang et al. 2013). Thus, TLR2 is a 
relevant target in glioma therapy, and is down-regulated by E804 and 
E804+TMF-treated GBM conditioned media. 
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Conditioned supernatants via E804-treated GBM cells had a significant 
inhibitory effect on the Wnt pathway in THP-1 macrophages. The Wnt pathway is 
a powerful regulator of embryonic development and cell differentiation, and has 
been implicated in the promotion of many cancer types such as colorectal 
cancer, hepatocellular carcinoma, and GBM (Bienz and Clevers 2000, Capurro et 
al. 2005, Duan et al. 2015, Kim et al. 2012). High levels of wnt in GBM cells aids 
in microglial recruitment, as well as tumor growth and invasion (Matias et al. 
2017), however the role of the Wnt pathway in macrophages is less known. I 
speculate that ligands present in E804-treated GBM supernatants are likely to 
have caused pathway down-regulation in macrophages cultured with the 
supernatant. Future studies should investigate candidate ligands such as PEDF 
(Ma et al. 2010), sclerostin (SOST), dickkopf (Dkk)1, or secreted frizzled-related 
protein (sFRP) (Bodine et al. 2009, Mason and Williams 2010). 
In addition to Wnt pathway down-regulation, key tumor-regulating Wnt 
ligands wnt7b and wnt10a (Kirikoshi and Katoh 2002, Kirikoshi et al. 2001) were 
down-regulated in THP-1 macrophages in response to treatment. Interestingly, 
macrophage-derived Wnt7b signaling has been found to promote tumor 
progression via increased angiogenesis and metastasis (Ojalvo et al. 2010). 
Additionally, in breast-to-brain cancer metastasis microglial cells have been 
shown to produce high levels of related Wnt ligand Wnt5a, which may aid in 
cancer migration (Pukrop et al. 2010). Therefore, inhibition of macrophage-
derived Wnt ligands is a viable therapeutic target. These data indicate candidate 
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genes, such as wnt7b and wnt10a, for future research investigating the effects of 
E804 and E804 + TMF on the tumor microenvironment. 
Furthermore, evidence for AHR and Wnt pathway crosstalk has been 
found in choriocarcinoma cells (Wu et al. 2018), liver progenitor cells 
(Procházková et al. 2011), prostate cancer cells (Chesire et al. 2004), and an in 
vivo mouse model for intestinal cancer (Kawajiri et al. 2009). AHR activation via 
dietary ligands in intestinal models has been shown to negatively regulate 
members of the Wnt pathway and thus restrict intestinal stem cell proliferation, 
indicating a tumor-preventative effect (Metidji et al. 2018). Because indirubins are 
metabolized rapidly, in a similar fashion to dietary-derived AHR ligands (Adachi 
et al. 2004), Wnt pathway modulation via indirubin treatment should be 
investigated further. Moreover, down-regulation of the Wnt pathway was no 
longer significant after addition of AHR-antagonist TMF, implying that this 
pathway is indeed tied to AHR signaling in this model. While E804 plus TMF 
treatment did not significantly alter Wnt pathway signaling, individual gene 
members were still affected. It is possible that a treatment regimen of E804 plus 
TMF could avoid negative affects of AHR pathway stimulation, while still targeting 
enough of the macrophage Wnt pathway to aid in decreased GBM tumor growth, 
invasion, and macrophages activation. 
I found the GO term “positive regulation of vasculature development” to be 
enriched in genes up-regulated by E804 plus TMF supernatants. Tumor 
vascularization has long been viewed as a major culprit in tumor growth and 
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metastasis, yet vascular endothelial growth factor (VEGF)/VEGF receptor 
inhibition has failed to increase GBM patient survival (Peterson et al. 2016). 
Indeed, Bevacizumab, the standard of care anti-VEGF antibody, has been found 
to enhance tumor cell invasion via promotion of hypoxic conditions (Keunen et al. 
2011). Dysregulation of angiogenesis has deleterious consequences in GBM and 
other cancers, thus treatments aimed at normalizing vasculature shows greater 
promise than inhibition of VEGF alone. The modulation of many genes involved 
in vascularization highlights yet another reason to investigate E804 plus TMF 
treatment in GBM cells and GAMs.  
One key observation from this study is the effect(s) of conditioned media 
from treated glioma cells on key components of steroid metabolism in the THP-1 
macrophage model. Expression of the gene cyp7b1 was suppressed in both cell 
lines by both E804- and E804+TMF, and cyp26b1 and cyp46a1 were reduced by 
E804 and not E804 + TMF. These genes and their protein products are involved 
in cholesterol and cholesterol-based steroid metabolism (Niwa et al. 2015), and 
the significance of these finding is unclear at the moment. Lipid metabolism by 
macrophages is the subject of intense research because of their role in 
cardiovascular diseases, and especially atherosclerosis (Remmerie and Scott 
2018).  The role(s) of altered cholesterol and steroid metabolism in macrophages 
under the influence of the glioma micro-environment is unclear. The observation 
that cyp19a1 (aromatase) expression is increased by supernatants from glioma 
cells treated with TMF suggests that the AHR has a role in the conversion of 
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testosterone to estradiol.  The same may be implied in the case of macrophage 
cyp11a1 due to treatment of LN-18 cells with TMF. This enzyme, known as side-
chain-cleavage, is a mitochondrial enzyme that converts cholesterol to 
pregnenolone (Hanukoglu 1992).  Also related to the AHR, high expression of 
cyp1a1 and cyp1b1 in macrophages treated with either E804 or E804+TMF 
suggests the presence of a strong AHR ligand in conditioned media.  It is 
possible that traces of E804 are in those supernatants, but this is unlikely 
because indirubins are metabolized very quickly to non-AHR active intermediates 
(Spink et al. 2003). More than likely, there are other ligands secreted by glioma 
cells leading to the induction of these two genes, and the many speculated 
candidates include kynurenines and their metabolites, as well as steroid 
intermediates. Overall, it is clear that future studies should focus on macrophage-
glioma cross-talk in terms of steroid and lipid metabolism. 
Because the focus of this study was on gene regulation in macrophages 
only, I have yet to elucidate the functional role these gene changes have on co-
cultured GBM cells. Future work in this lab aims to investigate genetic and 
phenotypic changes in GBM cells cultured with the supernatants of the treated 
macrophages herein. It is also relevant to note that published literature 
examining macrophage polarization looks at gene changes between 24 to 72 h. 
While 24 h is a commonly accepted time-point, due to the known plasticity of 
macrophages, it is possible that certain genetic markers for M1/M2 polarization 
occurred outside this window. Nonetheless, at 24 h clear changes in gene 
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regulation were observed, particularly in the Wnt pathway and TLR signaling. It 
remains to be investigated how these alterations in macrophage activation affect 
physiological changes in the tumor microenvironment. These findings suggest 
that both E804 and E804+TMF -treated GBM supernatants down-regulate gene 
profiles in THP-1 macrophages that are linked to tumor progression. Taken 
together with previous results from this lab (Scobie, Houke, and Rice 2019), I 
conclude that E804+TMF treatment represents an opportunity to modulate 
macrophage immune signaling within the GBM environment, and should be 
investigated further. Certainly, as the importance of the Wnt pathway in glioma-
GAM interaction continues to be elucidated, the potential clinical relevance of 
E804+TMF treatment should not be underestimated. 
121	
Acknowledgments 
I would like to acknowledge Clemson University for allotment of compute time on 
the Palmetto cluster. Additionally, Rooksana Noorai and the Clemson University 
Genomics and Bioinformatics Facility for their assistance in data sequence 
alignment and counting, made possible by the National Institute of General 
Medical Sciences Grant (P20GM109094). Library preparation and sequencing 
were performed by Novogene Co, Ltd. This work was funded, in part, by the Self-
Regional Healthcare Human Genetics Research Program, Greenwood Genetics 
Center, Greenwood, SC USA. 
122	
CONCLUSION 
This body of research aims to describe a new small molecule that could 
replace, or adjuvant, current chemotherapeutics such as temozolomide or 
carmustine. These drugs are DNA-alkylating agents that are infused into wafers 
and placed in the brain during surgical resection (Fukai et al. 2016). DNA-
alkylating agents, sometimes environmental carcinogens themselves, work by 
transferring an alkyl group to base pair guanine, causing strand breakage and 
subsequent widespread apoptosis (Kaina et al. 2007). Carmustine is extremely 
toxic: not only to target GBM cells, but also to surrounding healthy brain tissue. 
As an alternative, this study supports the use of E804-ladened wafers along with 
TMF to antagonize the AHR-associated responses of the compound.  
This study indicates that E804 possesses anti-inflammatory properties, 
with ability to inhibit GBM autocrine signaling such as IL-6 and VEGF, along with 
prior studies showing inhibition of STAT3 and CDKs. Herein, E804 was also 
shown to influence expression of key genes such as ifng, ptsg2, il12b, tnfa, il10, 
il13, pd1, pdl1, and hla. Additionally, I have shown that E804 regulates UPR 
stress response genes such as perk, gadd34, chop, atf6, and xbp1. UPR 
regulation is a therapeutic target for neuro-inflammatory diseases such as GBM, 
and E804 is a likely candidate. Importantly, E804 did not strongly induce a pro-
apoptotic gene profile, indicating it could be used as an immune regulator without 
causing widespread apoptosis to surrounding healthy brain tissue. E804 is an 
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AHR ligand, and therefore it induces the expression of genes associated with 
AHR activation. AHR activation has been associated with glioma-derived 
kynurenine production and further up-regulation of AHR itself. Thus, chronic 
activation of the AHR may help drive pro-tumor capabilities. Simultaneous 
treatment with AHR antagonist TMF may alleviate this particular property, and 
provide a non-toxic alternative to carmustine-laden wafers. 
E804 not only modulates inflammatory and stress response profiles in 
GBM, but also induces release of GBM-derived ligands that effect gene profiles 
in tumor-associated macrophages. The significant down-regulation of tumor-
related signaling such as the Wnt, TLR, and Cell Cycle pathways, indicates a 
clear role for E804 in future GBM studies. Addition of TMF yielded similar results 
as those obtained by E804 treatment alone, thus E804 plus TMF treatment 
should continue to be investigated. Key questions remain to be investigated 
before E804 or E804 plus TMF can progress to therapeutic potential. These 
include 1) match current genetic data with physiological and functional changes 
in THP-1 macrophages following culture with E804 and E804 plus TMF-treated 
GBM cells; 2) perform crosstalk study investigating backend signaling originating 
from macrophages to GBM cells, post original GBM treatment and macrophage 
culture with supernatants; and 3) determine therapeutic potential of E804 plus 
TMF for protection against GBM-induced animal lethality.
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